Senolytic Drugs Attenuate Osteoarthritis -Related Articular Cartilage Degeneration: A Clinic Trial  
[STUDY_ID_REMOVED]  
June 11 , 2021  
 
                                                                                                                                                                                                                                                                                                     
Senolytic Drugs Attenuate Osteoarthritis -Related  
       Articular Cartilage Degeneration: A Clinical Trial  
 
Protocol No.  2019 -16 
Original Date:  April 30, 2019  
Version 001  
Revision Date: May  31, 2019  
Version 002  
Revision Date: November 2 2, 2019  
Version 003  
Revision Date: June 3, 2020  
Version 004  
Revision Date: September 4, 2020  
Version 005  
Revision Date:  March 17, 2021  
Version 006  
Revision Date: June 11, 2021  
Version 007  
 
IND No . 144317  
 
Sponsor : 
Johnny Huard, Ph .D. 
 
Principal Investigator : 
[CONTACT_19617] A. Evans , M.D.  
 
 
Confidentiality Statement  
 
This document contains confidential information and is provided for the sole use of the 
Principal Investigator, Sub -Investigator(s), Staff, Institutional Review Board or Regulatory 
 
 
Clinical Protocol No. 2019 -16 
Version 00 7, June  11, 2021   
 Authorities.  By [CONTACT_11217], you agree to maintain the information as 
confidential and to use it only for the purpose of conducting  the study.  
 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page3 Table of Contents  
1.0 Steadman Philippon Research Institute Representatives  ................................ ........ 9 
2.0 Protocol Signature [CONTACT_3490]  ................................ ................................ ............................ 12 
3.0 Study Synopsis  ................................ ................................ ................................ ............ 13 
4.0 Terms and Abbreviations  ................................ ................................ .......................... 22 
5.0 Introduction  ................................ ................................ ................................ ................ 23 
 Background and Significance  ................................ ................................ .......... 23 
 Rationale  ................................ ................................ ................................ .......... 24 
 Pre-Clinical Data  ................................ ................................ .............................. 24 
5.3.1  Progeroid Musculoskeletal Symptoms in Z24-/- Mice Are Associated 
with Increased Senescent Cell Burden  ................................ ................. 24 
5.3.2  Primary Chondrocytes from Progeroid Z24-/- Mice Exhibit Reduced 
Chondrogenic Capacity in vitro  and Spontaneous Loss of Articular 
Cartilage Proteoglycan Content in vivo . ................................ .............. 25 
5.3.3  Z24-/- Mice Are More Sensitive to Injury -Induced OA Versus Age -
Matched WT Animals . ................................ ................................ ......... 25 
5.3.4  D/Q Protects from Spontaneous Proteoglycan Loss and OA -
Associated ADMTS4 Expression in Articular Cartilage  Of Z24-/- 
Mice.  ................................ ................................ ................................ ....26 
 Safety of Administering Fisetin to Subjects with OA  ................................ .....27 
6.0 Summary of Proposed Placebo Controlled Trial  ................................ .................... 28 
 Blinding ................................ ................................ ................................ ............ 30 
 Non-Prohibition of Additional/Alternative Procedures  ................................ ...30 
7.0 Study Medication  ................................ ................................ ................................ .......31 
 Fisetin  ................................ ................................ ................................ ............... 31 
 Placebo Control  ................................ ................................ ................................ 31 
 Supply  ................................ ................................ ................................ .............. 31 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page4 
 Administration of Study Medication  ................................ ............................... 32 
7.4.1  Route and Dosage  ................................ ................................ ................ 32 
7.4.2  Rationale for FIS Dose and Intermittent Dosing Schedule  .................. 32 
7.4.3  Dose  ................................ ................................ ................................ .....32 
7.4.4  Intermittent Dos ing Schedule  ................................ .............................. 33 
7.4.5  2 Month Duration  ................................ ................................ ................. 33 
7.4.6  Human Evidence of Safe Dosing  ................................ ......................... 33 
 Study Design and Duration  ................................ ................................ .............. 34 
7.5.1 Study Design  ................................ ................................ ........................ 34 
7.5.2  Study Duration  ................................ ................................ ..................... 34 
8.0 Study Objectives and Endpoints ................................ ................................ ............... 35 
 Objectives  ................................ ................................ ................................ ........ 35 
8.1.1  Primary Objective  ................................ ................................ ................ 35 
8.1.2  Secondary Objectives ................................ ................................ ........... 35 
 Study Endpoints  ................................ ................................ ............................... 35 
8.2.1  Primary Endpoint:  ................................ ................................ ................ 35 
8.2.2  Secondary Endpoints  ................................ ................................ ........... 35 
9.0 Stud y Population  ................................ ................................ ................................ ........ 37 
 Enrollment Criteria  ................................ ................................ .......................... 37 
9.1.1  Inclusion Criteria  ................................ ................................ ................. 37 
9.1.2  Exclusion Criteria  ................................ ................................ ................ 37 
10.0  Study Visits  ................................ ................................ ................................ ................. 40 
 Visit 2 (Baseline): (Within 3 months of Visit 1) ................................ .............. 40 
 Visit 3: Two Weeks after first dose of Fisetin or Placebo (+/ - 2 days)  ........... 41 
 Visit 4: Two Weeks from the S ubject's Last Dose of Fisetin or Placebo (+/ - 
10 days)  ................................ ................................ ................................ ............ 41 
 Visit 5: Six Months from the Subject's First Dose of Fisetin or Placebo (+/ - 
4 weeks)  ................................ ................................ ................................ ........... 42 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page5 
 Visit 6: [ADDRESS_1214282] Dose of Study Medication (+/ - 4 weeks)  .[ADDRESS_1214283] Dose of Study Medication (+/ - 4 weeks )  ........ 43 
 Unscheduled Visits and/or Subject Contact  ................................ ..................... 43 
            10.8     Phone Calls.............................................. .........................................................43   
11.0  Study Tools  ................................ ................................ ................................ ................. 44 
 Vital Signs (Visits 1, 3, 4, 5, 6)  ................................ ................................ ........ 44 
 Physical Exam: (Visits 1, 4, 5, 6) ................................ ................................ .....44 
 Range of Motion (ROM): (Visits 1, 4, 5, 6)  ................................ .................... 44 
 Blood Laboratory Analysis: (Visits 1, 3, 4, 5, 6)  ................................ ............. 44 
 Patient Reported Outcomes (PROs): (Visits 1, 2, 4, 5, 6)  ............................... 46 
 Imaging Assessment of OA  ................................ ................................ ............. 48 
11.6.1  Radiographic Assessment: (Visit 1) ................................ ..................... 48 
11.6.2  Quantitative Magnetic Resonance Imaging (MRI): (Visits 2, 5, 6)  .....48 
 Functional Performance Testing: (Visits 2, 5, 6)  ................................ ............. 49 
 Lower -Extremity Kinematics, Video -Motion Analysis:                                 
(Visits 2, 5, 6) ................................ ................................ ................................ ...50 
 Assessment of Muscle Strength, Isokinetic  Dynamometry:                                 
(Visits 2, 5, 6) ................................ ................................ ................................ ...50 
12.0  Study Management of Adverse Events  ................................ ................................ ....51 
 Definition  ................................ ................................ ................................ ......... 51 
 Recording Adverse Events  ................................ ................................ ............... 52 
12.2.1  Date of Onset and Resolution  ................................ .............................. 52 
12.2.2  Incidence  ................................ ................................ .............................. 53 
12.2.3  Relationship to Study Medication  ................................ ........................ 53 
12.2.4  Severity (Intensity) of Adverse Events  ................................ ................ 54 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page6 12.2.5  Expected and Unexpected Adverse Events  ................................ .......... 55 
12.2.6  Serious Adverse Events  ................................ ................................ .......55 
 Reporting of Adverse Events  ................................ ................................ ........... 56 
12.3.1  Function of the Medical Monitor and FDA  ................................ ......... 56 
13.0  Potential Risks to Study Subjects and Risk Mitigation  ................................ .......... 57 
 Associated with Fisetin Administration  ................................ ........................... 57 
 Risk Associated with Placebo Administration  ................................ ................. 57 
 Associated with MRI  ................................ ................................ ....................... 58 
 Associated with PRO Questionnaires  ................................ .............................. 58 
 Associated with Physical Exam  ................................ ................................ .......58 
 Associated with Blood Draw  ................................ ................................ ........... 59 
 Associated with Isokinetic Muscle Strength Testing  ................................ .......59 
 Associated with Motion Capture  ................................ ................................ .....59 
 Associated with Functional Performanc e Testing  ................................ ........... 60 
 Associated with Breach of Confidentiality  ................................ ...................... 60 
 Risk Analysis  ................................ ................................ ................................ ...60 
14.0  Stoppi[INVESTIGATOR_1869]/Termination of Study Enrollment  ................................ ................. [ADDRESS_1214284] rategy  ............................. 64 
 Endpoints  ................................ ................................ ................................ ......... 65 
15.5.1  Primary Endpoint  ................................ ................................ ................. 65 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page7 15.5.2  Secondary Endpoints  ................................ ................................ ........... 65 
 Statistical Power and Sample Size  ................................ ................................ ...67 
 Missing Data  ................................ ................................ ................................ ....67 
 Data Prepar ation and Maintenance of Blinding  ................................ ............... 68 
16.0  Principal Investigator’s Ethical and Regulatory Obligations  ................................ [ADDRESS_1214285]: Ethics and Good Clinical Practice  ................................ ......... [ADDRESS_1214286] Keepi[INVESTIGATOR_869860]  ................................ ........................... 71 
16.4.1  Study Medication Accountability  ................................ ........................ 71 
16.4.2  Study Documents  ................................ ................................ ................. 71 
16.4.3  Records Retention  ................................ ................................ ................ 71 
16.4.4  Records/Reports Inspection  ................................ ................................ .[ADDRESS_1214287] Completion  ................................ ................................ .......................... 75 
 Data Management  ................................ ................................ ............................ 75 
 Quality  of Data  ................................ ................................ ................................ .75 
 Data Security  ................................ ................................ ................................ ....75 
 Qualification of Study Staff  ................................ ................................ ............. 76 
 Training  ................................ ................................ ................................ ............ 76 
 Protocol Amendments  ................................ ................................ ...................... 76 
 Handling of Study Medication  ................................ ................................ ......... 76 
18.8.1  Dispensing and Labeling ................................ ................................ ......76 
18.8.2 Accountability  ................................ ................................ ...................... 77 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page8 18.8.3  Disposition of Unused Study Medication  ................................ ............ 77 
 Laboratory Qualification  ................................ ................................ .................. 77 
19.0  Disclosure and Confidentiality  ................................ ................................ ................. 78 
20.0  Declaration of Helsinki  ................................ ................................ .............................. 79 
21.0  References  ................................ ................................ ................................ ................... 80 
22.0  Appendices  ................................ ................................ ................................ .................. 84 
 Appendix A: Informed Consent  ................................ ................................ .......84 
Statement of Person Obtaining Informed Consent and  Research Authorization  ......... 107 
 Appendix B – Study Schemata  ................................ ................................ ......109 
 Appendix C -Augmented Numerical Rating Scale  ................................ ......... 110 
 Appendix D: Potential Drug Interactions with Fisetin  ................................ ..111 
 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page9 1.0                  Steadman Philippon Research Institute Representatives  
This Study is an Investigator Sponsored clinical trial to be carried out by [CONTACT_869907]  (SPRI) using grant 
support from the Office of Naval Research, US Department of Defense.  
 
Overall responsibility for the Study will be held by:  
[CONTACT_869908], Ph.D.  
Chief Scientific Officer and Director of the 
Center for Regenerative Sports Medicine  Steadman Philippon Research Institute  
[ADDRESS_1214288] ive, Suite 1000  
Vail, CO [ZIP_CODE]  
([PHONE_18025]  
[EMAIL_16467]  
 
Principal Investigator  
[CONTACT_19617] A Evans, M.D.  
Interventional Pain Management and 
Musculoskeletal Regenerative Medicine 
Specialist  
 
Sub-Investigator  
Raymond Kim , M.D.  
Adult Joint Reconstruction, Knee and Hip 
Arthroplasty Specialist  
 
 
Sub-Investigator  
Leslie B. Vidal, M.D.  
Shoulder, Hip, Knee and Sports Medicine 
Specialist  
 The Steadman Clinic  
[ADDRESS_1214289]  
Vail, CO [ZIP_CODE]  
([PHONE_18025]  
[EMAIL_16468]  
 
The Steadman Clinic  
[ADDRESS_1214290]  
Vail, CO [ZIP_CODE]  
(970) 476 -1100  
[EMAIL_16469]  
 
The Steadman Clinic  
[ADDRESS_1214291]  
Vail, CO [ZIP_CODE]  
(970) 476 -1100  
lvidal @thesteadmanclinic.com  
 
  
Clinical Protocol No. [ADDRESS_1214292]  
Vail, CO [ZIP_CODE]  
(970) 476 -1100  
avidal @thesteadmanclinic.com  
 
 
The Steadman Clinic  
[ADDRESS_1214293]  
Vail, CO [ZIP_CODE]  
(970) 476 -1100  
[EMAIL_16470]  
 
The Steadman Clinic  
[ADDRESS_1214294]  
Vail, CO [ZIP_CODE]  
(970) 476 -1100  
charles.ho @thesteadmanclinic.com  
 
Steadman Philippon Research Institute  
[ADDRESS_1214295]  
Vail, CO [ZIP_CODE]  
(970) 476 -1100  
[EMAIL_16471]  
 
 
 
  
Clinical Protocol No. [ADDRESS_1214296]., Ste. 300 
Overland  Park,  Kansas,  United  States  
(913)  661-1662  
[EMAIL_16472]  
 
The Study Team  
[CONTACT_21148] and his team will lead the clinical elements of the study. In addition, the teams of [CONTACT_32246] , [CONTACT_869955], [CONTACT_869956], and [CONTACT_869957]  at TSC will assist in enrollment of patients into the study. [CONTACT_125974] will read and analyze all MRI im aging. [CONTACT_869958] will lead a team of research associates for all duties related to functional performance, muscle strength testing, an d kinematics. 
There will also be a team of investigators and research associates  at SPRI  selected by [INVESTIGATOR_124]. Huard  to whom a ppropriated duties will be 
delegated according to their specific qualifications. Collectively Dr . Evans , [CONTACT_32246], Dr. L. Vidal, Dr. A. Vidal, [CONTACT_869957], [CONTACT_869959] , 
[CONTACT_125974], [CONTACT_869960]  and their designees are referred to as the “Study Team” .  
 
Primary Conta ct for the Study  
Johnny Huard, Ph.D.  
Chief Scientific Officer and Director of the 
Center for Regenerative Sports Medicine  
 Steadman Philippon Research Institute  
[ADDRESS_1214297] ive, Suite 1000  
Vail, CO [ZIP_CODE]  
(970) 476 -1100  
[EMAIL_16467]  
 
  
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page12 2.0                Protocol Signature [CONTACT_869948], Senolytic Drugs Attenuate Osteoarthritis -Related Articular 
Cartilage Degeneration: A Clinical Trial with attachments, and provides the necessary assurances that this trial will be conducted in 
compliance of all stipulations of the protocol, including all s tatements regarding confidentiality, and according to local legal and, 
regulatory requirements, International Conference on Harmonization Good Clinical Practice E6 (ICH -GCP), and applicable US 
regulatory requirements.  
 
 
Principal Investigator:   ___________________________________________________  
Print/Type  
Title:   __________________________________________________________________  
 
Signed:   ________________________________________ Date :  _________________  
 
 
 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page13 3.0                Study Synopsis  
 
Sponso r/ Investigator Sponsored 
Study  Johnny Huard , Ph.D.  
Study Title:  Senolytic Drugs Attenuate Osteoarthritis -Related Articular Cartilage Degeneration:  A Clinical 
Trial  
Protocol Number:  2019 -16 
Study Design:  Randomized, double -blind, placebo controlled  
Study Duration:  Approximately 3 6 months  
Enrollment 1 8 months  
Follow -up 18 months  
Randomization:  Subjects are to be assigned to one of two treatment groups using a 1:1 ( Fisetin/placebo) 
randomization scheme.   
Study Arms/Medication  Active Treatment:  Fisetin 100 mg capsules (~20 mg/ kg/ day) will be administered orally for 
two consecutive days (days 1 and 2) followed by 28 days off.  A second course will be given 
for two c onsecutive days (days 3 1 and 3 2) Placebo Control:  Appearance matched capsule p.o. 
dose to match the number of capsules as if subjects were receiving active treatment. Placebo 
capsules will be administered orally for two consecutive days (days 1 and 2) foll owed by 28 
days off.  A second course will be given for two consecutive days (days 3 1 and 3 2) 
Blinding Procedure:  The b lock randomization chart will be securely kept by [CONTACT_869909][INVESTIGATOR_78700] (point of subject distribution).  All study subjects and other 
Study Team members including the Principal Investigator [INVESTIGATOR_869861] 
18 months follow -up.  In addition, any individuals engaged by [CONTACT_079] [INVESTIGATOR_869862]/or document assessment of study endpoints will be blinded to treatment.   
Sample Size and Study 
Population:  A total of 100 male or female subjects 40-80 years of age will be recruited from a single clin ical 
site, where the Principal Investigator [INVESTIGATOR_869863].  
 
Objectives:   Primary Objective  
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page14 To evaluate as compared to placebo:  
 
The safety of administering Fisetin in  subjects with osteoarthritis  (OA)  of the knee . 
 
Secondary Objectives  
To evaluate as compared to placebo:  
 
1. Reduction of pro -inflammatory and cartilage degenerating SASP markers;  
 
2. Improvement in physical function of the Study  Knee; 
 
3. Improvement in patient reported outcomes;  
 
4. Improvement in the quality of articular cartilage in the  Study Knee with quantitative 
magnetic resonance imaging  (MRI) ; 
 
5. Reduction in t ime to conversion to alte rnative treatment . 
Endpoints:  
 
 Primary Endpoint:  
Occurrence of adverse events.  
 
Secondary Endpoints  
Statistically significant as compared to placebo:  
1. Improvement in serum measures of inflammation and cartilage degenerating senescence 
associated secretory phenotype ( SASP ) markers;  
2. Improvement in lower -extremity kinematic testing with video -motion analysis; 
isokinetic dynamometry testing, functional perfo rmance testing, range of motion  
(ROM) ; 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page15 3. Improvement in patient reported outcomes  (PROs) , including: IKDC, Lysholm, 
TEGNER, WOMAC and SF -12 surveys;  
4. Improvement in the quality of articular cartilage in the knee joint as measured b y T2 and 
T1rho relaxometry;  
5. Days from day one of Study Medication intake to conversion to alternative therapy.  
 
Additionally, we will review and discuss any possible correlation among secondary endpoint 
results.  
 
Inclusion Criteria  Subjects will be included if all the following crit eria are met:  
1. Are male or female, ages 40 -80; 
2. Are willing to comply with all study related procedures and assessments;  
3. Are ambulatory as defined by [CONTACT_869910];  
4. Radiographic evidence of Kellgren -Lawrence grade II -IV osteoarthritis in one or both 
knees;  
5. Scores 4 -10 on the Numerical Rating Scale (NRS) for pain;  
6. Stable dose of screening /baseline medications for at least 2 months prior to the 
anticipated date of study drug dosing.  
Exclusion Criteria:  
 Subjects will be excluded if any of the following criteria are met:  
1. Females who are nursing, pregnant or planning to become pregnant durin g the duration 
of study drug dosing;  
2. Males who do not wish to abstain from sex or use contraceptive protection  during study 
drug dosing and for [ADDRESS_1214298] dose ; 
3. Subjects who do not have the capacity to consent themselves;  
4. Subjects who are unable to tolerate oral medication;  
5. Subjects having previously undergone any of the following treatments in the stated time 
window : 
-Surgery on the Study Knee in the past 6 month s; 
 
  
Clinical Protocol No. [ADDRESS_1214299] 6 months prior to enrollment and the operative knee is asymptomatic ; 
           -Patients who have undergone arthroscopic surgery                 
            (including microfracture and meniscectomy) on the StudyKnee  in the last [ADDRESS_1214300] arthroscopic surgery on either knee at any 
time during the study period;  
            -Steroid injection, including extended -release corticosteroid (e.g., Zilretta®) within the 
last 5 months;  
            -Biologic (platelet -rich plasma, bone marrow, adipose tissue/cells) or hyaluronic acid 
injection into the Study Knee in the past 6 months;  
6. Subjects with any of the following drug/medication statuses:  
             - Currently taki ng Losartan;  
-Currently taking Warfarin or related anticoagulants;  
- Opi[INVESTIGATOR_869864] 8 weeks and are not willing to discontinue these 
medications through the duration of the study;  
             - Senolytic agents taken within the past 6 months and are not willing to discontinue these 
medications through the duration of the study, including: Fisetin, Quercetin, Luteolin, 
Dasatinib, Pi[INVESTIGATOR_293119], or Navitoclax;  
             -Drugs that induce significant cellular stress and are not willing to discontinue these 
medications through the duration of the study , including alkylating agents, 
anthracyclines, platins, other chemotherapy drugs;  
- Subjects taking the following other drugs if they cannot be held (per the Principal 
Investigator) for at least 2 days before and during administration of Fisetin : cyclospor ine, 
tacrolimus, repaglinide, and bosentan ; 
7.   Subjects with any of the following disease statuses:  
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page17             -Significant liver disease (i.e. greater than or equal to 2x the upper limit of normal 
bilirubin levels) or as in the opi[INVESTIGATOR_456571] l Investigator;  
            -Significant renal disease (eGFR of <60 ml/min/1.73m2) or as in the opi[INVESTIGATOR_160507];  
            -History of other formally diagnosed joint diseases including, osteonecrosis, acromegaly, 
Paget's disease, Eh lers-Danlos Syndrome, Gaucher's disease, Cushing’s syndrome, 
Stickler's syndrome, joint infection, hemophilia, hemochromatosis, or neuropathic 
arthropathy of any cause;  
            -Any active systemic autoimmune disease with musculoskeletal involvement or  any 
history of systemic inflammatory arthritis;  
            -Patients with type 1 or 2 diabetes (HbA1c > 6.5%) and/or taking medications that affect 
insulin levels, including: Metformin (within the last week), Glucocorticoids (within the 
last month), Acarbose (within the last week) ; 
8.   Subjects unable to safely practically undergo an MRI (BMI > 40 kg/m2) or size exceeding 
limits of MRI equipment, implanted metal in study knee near joint surface, incompatible 
implant/device, severe claustrophobia;  
9.   Subjects that have any medical condi tion, including laboratory findings and findings in the 
medical history or in the pre -study assessments, that in the opi[INVESTIGATOR_684033] 
a risk or contraindication for participation in the study or that could interfere with the study 
objectives, conduct or evaluation or prevent the patient from fully participating in all aspects of 
the study.  
 
 
Screening  
 Visit 1 ( Screening /Enrollment ) 
At the first patient visit, the following procedures will be performed:  
1. Full explanation of the clini cal study, execution of Informed Consent, copy of signed 
informed consent sent home with research subject ; 
2. Subject will be assigned a de -identified study number;  
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page18 3. Vital signs;  
4. Medical and surgical history;  
5. Demographic information;  
6. Details of injury;  
7. Severity of injury;  
8. Medications;  
9. Physical exam with  range of motion (ROM)  of the target limb;  
10. BMI;  
11. Urine pregnancy test for Women of Child Bearing Potential (WOCBP) ; 
12. Blood analysis;  
13. Completion of augmented  PROs, including:  NRS, IKDC, Lysholm, TEGNER, 
WOMAC  and SF -12; 
14. A radiograph of the target knee will be performed to confirm the presence of Kellgren -
Lawrence grade II -IV OA;  
15. The patients’ medical record will be reviewed, and the subject will be interviewed to 
determine if inclusion/exclusion criteria are met; 
16. Randomization.  
 
Patients who have met all eligibility criteria will be assigned, 1:1 via block randomization, to 
one of the two blinded study groups.   
Visit 2 ( Baseline ) (Within 3 months of Visit 1)  
Some procedures performed in this visit may be performed in Visit [ADDRESS_1214301] for Women of Child Bearing Potential (WOCBP ) 
2. Quantitative MRI;  
3. Kinematic movement;  
4. Assessment of muscle strength, isokinetic dynamometry ; 
5. Functional performance testing . 
 
  
Clinical Protocol No. [ADDRESS_1214302]’s assigned randomization code  the study medication  will be obtained. 
The subject will take the first dose of study medication  at the clinic .  
 
Subjects will be instructed to self -medicate for  day 2 followed by 28 days off.  They will be 
instructed to begin a second course of treatment for two consecutive day s (days 3 1 and 3 2). 
 
Subjects will be reminded at Visit [ADDRESS_1214303] Follow -up: All adverse events and protocol deviations will be assessed at each follow -up visit.  
 
Visit 3: Two Weeks  after first dose of Fisetin or Placebo (+/- 2 days)  
All subjects will return to the study site 2-weeks  from the subject's last dose of Fisetin  or 
placebo. The following procedures will be performed:  
1. Blood Analys is 
 
Visit 4: Two Weeks from  the Subject's Last Dose of Fisetin or Placebo  (+/- 10 days)  
All subjects will return to the study site 2-weeks  from the subject's last dose of Fisetin  or 
placebo. The following procedures will be performed:  
1. Vital signs;  
2. Medical and surgical h istory;  
3. Physical exam with ROM of target limb;  
4. Blood analysis;  
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page20 5. Medications;  
6. Completion of augmented  PROs, including:  NRS, IKDC, Lysholm, TEGNER, 
WOMAC and SF -12; 
7. Protocol deviation assessment;  
8. Adverse event assessment.  
 
Visit 5: Six Months from  the Subject's First Dose of Fisetin or Placebo  (+/- 4 weeks)  
1. Vital signs;  
2. Medical and s urgical history;  
3. Physical exam with ROM of target limb(s);  
4. Blood analysis;  
5. Completion of augmented  PROs, including:  NRS, IKDC, Lysholm, TEGNER, 
WOMAC and  SF-12; 
6. Medication ;  
7. Protocol deviation assessment;  
8. Adverse event assessment ; 
9. Quantitative MRI;  
10. Lower -extremity kinematic testing with video -motion analysis;  
11. Isokinetic dynamometry testing;  
12. Functional performance testing . 
 
Visit 6: 12 Months following Firs t Dose of Study Medication  (+/- 4 weeks)  
All procedures performed in Visit 5 will be repeated.  
 
Additional Remote Follow -up 
In addition to the in -clinic follow -up visits above, the following remote follow -up will be 
conducted:  
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page21 • Once Every  [ADDRESS_1214304] 6 weeks of  Study Medication Treatment  then 
Once a Week for an ADDITIONAL 6 weeks   
Subjects will complete an augmented NRS questionnaire.  
 
• At 18-Month s After First Dose of Study Medication  (+/- 4 weeks)  
Subjects will complete the augmented PROs  electronically , including: NRS, IKDC, 
Lysholm, TEGNER, WOMAC and SF -12. 
 
• Phone Calls  
Subjects will be contact[CONTACT_869911].  
 
Statistical Methods  Please refer to Section 15.[ADDRESS_1214305] of Care  
SPRI  Steadman Philippon Research Institute  
TSC  The Steadman Clinic  
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page23 5.0                Introduction  
 
 Background and Significance  
The Steadman Clinic  (TSC)  and the Steadman Philippon Research Institute  (SPRI) are proposing a Phase [ADDRESS_1214306] safety and efficacy data on the use of Fisetin  (FIS), which is a nutritional supplement and senolytic agent , in treating patients 
with  Osteoarthritis (OA) of the knee.  This study is entitled:  Senolytic Drugs Attenuat e Osteoarthritis -Related Articular Cartilage 
Degeneration: A Clinical Trial.  
 
Recently, several senolytic compounds that selectively kill senescent cells in vitro and in vivo without affecting quiescent or proliferating 
cells were identified1.  These senolytic drugs target and inhibit anti -apoptotic pathways that are upregulated in senescent cells , thereby 
[CONTACT_869912] -Associated Secretory Phenotype ( SASP ) factors.  
 
As further discussed in 5.[ADDRESS_1214307] demonstrated in pre -clinical studies that treatment with senolytic drugs including 
(FIS, Dasatinib (D), Quercetin (Q) and Alvespi[INVESTIGATOR_626435]) can reduce the incidence/severi ty of many age -related disorders , including OA 
in naturally aged and progeroid mice (accelerated aging). These  studies have shown that senolytic treatment (D/Q and FIS) can delay 
articular cartilage degeneration in a murine model of natural and accelerated  (progeria) aging.  
 
Based on this promising pre -clinical data, we believe it may be possible to delay or even reverse joint degeneration, damage to ligaments , 
menisci, cartilage, thereby [CONTACT_869913] -level function and preservation of  quality of life.  
 
In this randomized , double -blind, placebo -controlled clinical trial , we intend to measure and compare safety via the gathering of all 
adverse events and preliminary evidence of efficacy through recording of SASP , inflammatory biomarkers  and senescent cells .  In 
addition,  magnetic resonance imaging  (MRI ) exams , self -reported outcomes, functional performance and other relevant clinical data  
will be gathered .   Possible correlation among outcomes, both structural and non-structural , will be described.   
 
Each subject is  to be followed for [ADDRESS_1214308] -traumatic OA (PTOA) is characterized by 
[CONTACT_869914]9-[ADDRESS_1214309] shown that local clearance of sene scent cells genetically within the 
intra-articular space significantly reduces development of injury -induced OA and promot es a pro -regenerative environment15. Thus, the 
link between cellular senescence and OA pathogenesis is strong, highlighting senolytic drugs as a very appealing a nd innovative 
approach to prevent or treat OA.  
 
There are currently three Phase II clinical trials designed to investigate F IS in senescence associated diseases , including frailty, 
inflammation, diabetic and chronic kidney disease [STUDY_ID_REMOVED], [STUDY_ID_REMOVED] , [STUDY_ID_REMOVED]. To date there have been no human 
studies that have evaluated senolytic drugs for the treatment of knee OA . 
 
 Pre-Clinical Data  
The following pre -clinical studies present an animal model for the study of OA, a proof of concept connection between cell 
senescence  and loss of chondrogenic capacity, proteoglycan content , which may lead to OA, as well as the potential protective effect 
of senolytic agent s. 
 
5.3.1 Progeroid Musculoskeletal Symptoms in Z24-/- Mice Are Associated with  Increased Senescent Cell Burden  
Muscle derived stem/progenitor cells (MDSPCs) are a population of adult muscle progenitors that the SPRI  laboratory uses for various 
regenerative medi cine applications.  MDSPCs isolated from skeletal muscle of 2 months old Z24-/- Mice with progeroid symptoms were 
found to have significantly elevated β -galactosidase  (β-gal+) cells when compared to Wild -Type (WT) healthy control cells.  β -gal is a 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page25 hydroly tic enzyme whose activity is upregulated during aging and an established marker for cellular senescence16. Further, β -gal 
expression is associated with increased expression of other senescence associated cell cycle regulator transcription factors , including 
p16 and p21. These transcripts are elevated in senescent cells and keep them in a non -proliferative state, a hallmark of senescence. 
Senescent cells were also detected in gastrocnemius  muscle  from progeroid  Z24-/- mice.   
 
It  has been reported that skeletal muscle histopathology are seen with a dysfunction of MDSCs in Z24-/- mice17. Therefore, we believe 
these musculoskeletal pathologies ob served in Z24-/- mice are associated  with increased senescent cell  burden.  
 
5.3.2 Primary Chondrocytes from Progeroid Z24-/- Mice Exhibit Reduced Chondrogenic Capacity in vitro  and 
Spontaneous Loss of Articular Cartilage Proteoglycan Content in vivo . 
Z24-/- mice  are deficient in the metalloprotease Zmpste24, which results in the accumulation of unprocessed Lamin A, very similar to 
progerin in patients with Hutchinson -Gilford progeria syndrome (HGPS).  This causes blebbing of the nuclear membrane18.  Disruption 
of the nuclear envelope due to Lamin A accumulation leads to destabilization of heterochromatin, DNA damage, and eventual cel l cycle 
arrest and senescence19.  Chondrocytes are the sole cell type in articular cartilage and ar e responsible for maintaining the specialized 
extracellular matrix proteoglycan content on joint surfaces19.  To gauge the effects of Zmpste24 loss specifically in chondrocytes, 
primary costal chondrocytes from 2 -month -old Z24-/- mice were isolated as previously described20. As expected, chondrocytes from 
Z24-/- mice lacked Zmpste24 expression, exhi bited nuclear blebbing and were found to have reduced expression of type II collagen 
(Col2).  
 
Accordingly, pellet culture of isolated chondrocytes were significantly smaller with decreased Col2 signal and toluidine blue  stain 
intensity indicating decreased  chondrogenic capacity.  These data suggest that progeroid Z24-/- chondrocytes are sensitive to senescence 
and dysfunction which may initiate or potentiate OA.  Indeed, safranin O staining of Z24-/- articular cartilage revealed  obvious loss of 
proteoglycan  content versus WT at only 5 months of age.  
 
5.3.3 Z24-/- Mice Are More Sensitive to Injury -Induced OA Versus Age -Matched WT Animals . 
PTOA accounts for roughly 12% of OA cases.  Although associated with acute initiation, PTOA is characterized by [CONTACT_869915] - associated   OA21,22.  Surgical destabilization of the medial meniscus (DMM) is an established method to model post -
traumatic OA that allows for the immediate initiation of OA with more severe phenotypes including overt inflammation, cartilage 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page26 degeneration, and osteophyte formation. These effects can be detected histologically and radiologically23.  Given that Z24-/- animals 
showed diminished proteoglycan content, an early sign of OA, we hypothesized that they might be more sensitive to injury - induced 
OA.  
 
With  this in mind, a small cohort of Z24-/- and WT mice received DMM as described23, then were sacrificed at 12 weeks. Changes in 
their articular  cartilage was examined histologically.  
 
As expected, DMM in WT mice resulted in decreased proteoglycan content within the articular cartilage  as well as elevated MMP -13 
and ADMTS -5 expression (ECM degrading enzymes up -regulated during OA).  However, cartilage degeneration was significantly 
worse in  Z24- mice, when compared to normal mice, demonstrating their sensitivity to injury -induced OA.     
 
These data highlight the utility of the Z24-/- model to evaluate senolytic therapi[INVESTIGATOR_869865] -induced OA.  
 
5.3.4 D/Q Protects from  Spontaneous Proteoglycan Loss and OA -Associated ADMTS4 Expression in Articular 
Cartilage  Of Z24-/- Mice.  
As a proof of concept, a pi[INVESTIGATOR_869866] + Quercetin (D/Q) (5 mg/kg; 50 mg/kg) using Z24-/- mice.  Mice  were  
administered  D/Q via oral gavage  as a single  dose (D/Q sin) at 4 months  of age, or monthly dose  starting  at 2 months  of age (D/Q mul) prior  
to sacrifice at 5 months old.  
 
Quite surprisingly, a single dose of D/Q alone was enough to mitigate proteoglycan loss in articular cartilage of Z24 -/- mice.  These 
effects were even more dramatic in mice treated with multiple doses of D/Q demonstrating a dose response to D/Q treatment thr oughout 
the short 3 months treatment window. In  addition, Z24-/- mice in the D/Q mul group were found to have decreased  ADMTS -4 positive  cells 
indicative  of less ECM degradation.  
 
While  only preliminary,  and from  a single time point (5 months), these data strongly suggest that senolytic drug treatment may facilitate 
the retention of articular  cartilage proteoglycan content and possibly mitigate age -related OA pathogenesis.  
 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page27 
 Safety of Administering Fisetin to Subjects with OA 
Fisetin (FIS)  is available as a dietary supplement.  Other flavonoids , such as Q uercetin  (Q), have been safely used in clinical trials in 
amounts up to [ADDRESS_1214310] been shown to inhibit cytochrome P450 2C9. Therefore, precaution will be taken to 
avoid significant drug -drug interactions, such as with warfarin26. 
 
More recent (unpu blished) data in humans has been submitted to FDA in an Annual Report containing data gathered in three human 
studies of Fisetin  from 3/5/2018 to 02/28/2019 under approved IND 134052.  James L. Kirkland, M.D., Ph.D. of the Mayo Clinic  as 
Sponsor -Investiga tor of this referenced IND has authorized FDA via separate submission (1571 SN0007) and [CONTACT_869961], Ph.D. 
the proposed Sponsor -Investigator for this IND application, to reference any and all information contained in IND 134052.  
 
Under this reference d IND [ADDRESS_1214311] been treated at a dose of Fisetin 20mg/kg/day, orally 
for [ADDRESS_1214312] been treated with Fisetin 20/mg/kg/day, orally for [ADDRESS_1214313] experienced a transient reduction in kidney function (creatinine increased from 2.76 to 3.68) on Day 14 after 
administration of the randomized intervention (either placebo or Fisetin).  Interim safety labs were obtained which showed return of 
kidney function (creatinine 2.40) at Day 23.  The change in kidney function was determined to be possibly related to the administration  
of Fisetin or Placebo.  Given  this occurrence, we have  incorporate d routine laboratory testing including serum creatinine at study visits 
1, 3, 4 , 5 and 6 . 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page28 6.0                Summary of Proposed Placebo Controlled Trial  
Our objective is to determine (through the performance of an adequate and  well-controlled clinical trial ) if the administration of Fisetin 
(FIS)  safely reduces inflammation and pain, reduces senescent cell burden , mitigates cartilage degeneration, and improves joint function 
in patients  with moderate to severe  OA of the knee.  
 
Patients suffering from OA of one or both knees will be recruited from the clinical practice of the Principal Investigator [INVESTIGATOR_869867].   Patients 
diagnosed with Kellgren -Lawrence grade II -IV OA of the knee via radiographic analysis, who meet all enrollment criteria will be offered 
the opportunity to participate in this study.  
 
At the first visit, e ach potential subject will be fully informed regarding all aspects of the proposed study and will be required to rev iew 
and sign a full, IRB approved, Informed Consent Form (ICF) attached as Appendix A  in Section 22.1.  Subjects who sign Informed 
Consent will be scre ened by a member of the Study Team .  The patients’ medical record will be reviewed to determine if medical history 
indicates that the eligibility  criteria are met.  If so, s ubjects will be screened for OA and senescent cells by T -Cell assay , C12FDG Flow 
assay, and by [CONTACT_869916] . Further blood analyses will be performed .  
 
Subjects w ho meet eligibility criteria w ill be assigned, 1:1 via block randomization, to one of the two blinded study groups.  FIS and the 
inactive placebo are collectively referred to as Study Medication.  
 
n=36: Active Treatment: FIS: 100 mg capsules (~20 mg/ kg/ day);  
n=36: Placebo Control: Appearance matched capsules (dose to match the number of capsules as if subjects were receiving active  
treatment).  
 
 
At visit two, Quantitative  MRI, kinematic movement  and strength testing , range of motion ( ROM ) and functional performance testing .  
Subjects will complete  numerous patient reported outcomes tools , including an augmented patient reported outcomes (PROs), includi ng 
numerical rating scale ( NRS ) for pain  (as described in Section 11.5) of this protocol International Knee Documentation Committee  
(IKDC ), Lysholm, T egner , Western Ontario McMaster Universities Osteoarthritis Index ( WOMAC ) and short form -12 health survey 
(SF-12), which will provide a baseline assessment of joint pain and function.   
 
  
Clinical Protocol No. [ADDRESS_1214314]’s  assigned 
randomization code , and the medication will be obtained from the pharmacy . Subjects will take their first dose of study medication  at 
the clinic.   
 
Then, s ubjects will self -medicate on day 2 followed  by 28 days off.  A second course will be taken for two consecutive days (days 3 1 
and 3 2). Day [ADDRESS_1214315] 
dose and then weekly thereafter for an additional 6 weeks.  
 
Subjects will return to the clinic for a blood draw (visit 3) [ADDRESS_1214316] dose of study medication  (+/- 2 days) . 
 
Subjects will be called on the telephone three times during study medication  administration to capture adverse events and to remind 
subjects to take the next dose of study medication . 
 
On the fourth  visit ([ADDRESS_1214317] medication dosage +/ - 10 days) subjects  will be asked to return to the study site .   A review of 
study medication  and concomitant medication use , vital signs, and a physical exam with ROM will be performed.  The subject will be 
asked to complete the augmented  NRS, IKDC, Lysholm, TEGNER, WOMAC and SF -12.  All adverse events and protocol deviation s 
will be  document ed. A blood draw will be performed to measure  senescent cells by T -Cell assay and by [CONTACT_869916].  
Further blood analyses will be performed .  
 
At 6-, 12- and [ADDRESS_1214318] dose  (Visit s 5 and 6) subject s will be evaluated at the study site . A review of concomitant medications , 
vital signs, and a physical exam with ROM will be performed.  All adverse events and protocol deviations will be documented.  A blood 
draw will be performed to measure  senescent cells by T -Cell assay and by [CONTACT_869916].  Further blood analyses will be 
performed . A quantitative MRI, lower -extremity kinematics testing with video motion analysis, isokinetic dynamometry testing, and 
functional performance test ing will be performed.  
adverse event and protocol deviation data will be collected.  
 
 Blinding  
Blinding will be maintained through study follow -up until the last subject has been seen at [ADDRESS_1214319] evaluation , data management  and analysis  (including the Principal 
Investigator) will be blinded. In addition,  any individual engaged by [CONTACT_45822]  [INVESTIGATOR_869868] , laboratory testing  
and and/or verification of data  will be blinded to treatment.   
 
Those unblinded include the Group Allocation Manager (not a member of the Study Team ) that will be responsible for maintaining 
group assignment . In addition , the pharmacist responsible for medication distribution (including their team) will maintain a similar log 
and need to be unblinded to distribute study medication  accurately.                
 
 Non-Prohibition of Additional /Alternative Procedures  
In the even t that a subject feels that he/she is unresponsive to the Study Medication ( Fisetin  or placebo) and/or and is having difficulty 
managing knee pain , he/she will be free to receive a single corticosteroid intra -articular knee injection and still remain in th e study.  In 
addition, subjects will be free to seek alternative treatment at any time ; however , this may necessitate withdraw from the study as further 
described in Section 14.3 of this protocol.  
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page31 7.0 Study Medication  
 
 Fisetin  
Fisetin ( FIS) is widely available as a dietary supplement.  To our knowledge, F IS has not been withdrawn from any market globally.    
 
FIS (3,3’,4’,7 -tetrahydroxyflavone) is a member of the flavonoid family, a family of naturally occurring polyphenolic compounds. F IS, 
a high Trolox -equivalent antioxidant, is present in low concentrations in many fruits and vegetables , such as apples, persimm on, grapes, 
onions, and cucumbers , with the highest concentration found in strawberries (160µg/g)27-29. Fisetin capsules supplied are to be opaque 
blue in color.  
 
 Placebo Control  
The placebo comparator used for this study is to be manufactured using the same size #3 opaque blue capsule.  Each placebo ca psule is 
mainly composed of cellulose along with som e coloring agents to approximate the appearance of the active capsule.  
 
 Supply  
While Fisetin ( FIS) is currently available and marketed as a dietary supplement , this study will use a product manufactured under cGMP 
conditions.  The FIS will be supplied in [ADDRESS_1214320] Operating Procedures 
maintained by [CONTACT_869917][INVESTIGATOR_78700].  
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page32  
 Administration of Study Medication  
7.4.1 Route and Dosage  
Fisetin (FIS)  100 mg capsules (~20 mg/ kg/ day) will be administered orally for two consecutive days (days 1 and 2) followed by 28 
days off.  A second course will be given for two consecutive days (days 3 1 and 3 2) 
Placebo (visually identical) will be taken orally using the same dosing schedule described for F IS.  Number of capsules per day will be 
the same number as if receiving F IS.  
 
There are no recommended dosing adjustments for kidney or liver dysfunction.   
 
Subjects will be instructed to complete dosing in as short of a time as possible, with a goal of [ADDRESS_1214321] ion of the capsules.  They will further be instructed not to increase medication dosing should a particular dose 
be missed.  
 
7.4.2 Rationale for F IS Dose and Intermittent Dosing Schedule  
 
7.4.3 Dose  
We previously treated 4 male and 4 female 8 -month -old C57/Bl6 mice w ith FIS 500 mg/kg/day, (a dose 25-fold higher than the dose to 
be used in this clinical trial)  by [CONTACT_869918] f emale mice 
treated with control.  We found no evidence of substantia l toxicity, as assessed by [CONTACT_811592], food intake, and respi[INVESTIGATOR_869869] (Comprehensive Laboratory Animal Monitoring System, Columbus Instruments) for [ADDRESS_1214322] 
FIS dose.  
 
In addition, we administered 100 mg/kg/day for 2 consecutive days by [CONTACT_1966] (a dose five times the dose proposed in in this clinical 
trial) to two older Rhesus monkeys, ages [ADDRESS_1214323] treated m ice with F IS 50 mg/kg/day for weeks without evidence of toxicity30. 
 
Based on  this data and considering the high rate of drug metabolism in mice compared to humans and differences in physiology between 
non-human primates and humans, we believe that a daily dose of ~20 mg/kg /day is a safe dosage at which to complete this early stage  
clinical study. In addition, this smaller dose serves to minimize excessive pi[INVESTIGATOR_869870].  
7.4.4 Intermittent Dosing Schedule  
Senolytic drugs (including FIS) can effectively kill senescent cells with one to two doses given systemically1. We believe that allowing 
two week breaks between dosing will be more tolerable to patients as compared to sustained dosing, therefore minimizing proto col 
deviations.   
 
We further believe that intermittent dosing may min imize the occurrence of potential drug -drug interactions and hopefully decreasing 
the frequency or magnitude of any potential side effects further discussed in Section 13.1of this protocol.  
7.4.[ADDRESS_1214324] chosen a 2-month  (32 days) dose duration based upon pre-clinical studies reviewed in  Section 5.[ADDRESS_1214325] treated mice with our proposed dose and  more, for over two months (equivalent of ~20 y ears in the human lifespan). 
Considering the comparative life span between the mouse model and of humans, we believe that a 2-month  duration is a safe and 
effective length of time.  
7.4.6 Human Evidence of Safe Dosing  
As discussed in Section 5.4 there appears  to be no serious safety barriers to administration of  
Fisetin at the proposed dosage.  
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page34 
 Study Design and Duration  
7.5.1 Study Design  
This is a prospective, randomized, placebo controlled, double blind study to be conducted at the Steadman Clinic and the Stea dman 
Philippon Research. A total of no more than 100  will be randomized 1:1 to receive either Fisetin  (FIS)  or placebo.  
7.5.[ADDRESS_1214326] visit September  1, 2022.  
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page35 8.0                   Study Objectives  and Endpoints  
 Objectives  
8.1.1 Primary Objective  
To evaluate  as compared to placebo :  
1. The safety of administering Fisetin ( FIS) in subjects with osteoarthritis  (OA) . 
 
8.1.2 Secondary Objective s 
To evaluate as compared to placebo:  
 
1. Reduction of pro-inflammatory and cartilage degenerating SASP markers ; 
2. Improvement in p hysical function  of the target knee ; 
3. Improvement in PROs ; 
4. Improvement in the quality of articular cartilage in the knee joint ; 
5. Reduction in  time to conversion to alternative treatmen t. 
 
  Study Endpoints  
8.2.1 Primary Endpoint : 
1. Occurrence of adverse events.  
8.2.2 Secondary Endpoints  
Statistically significant as compared to placebo:  
1. Improvement in serum  measures of inflammation and cartilage degenerating SASP markers ; 
2. Improvement in l ower -extremity kinematic testing with video -motion analysis;  isokinetic dynamometry testing , functional 
performance testing , ROM ; 
3. Improvement in IKDC, Lysholm, TEGNER, WOMAC and SF -12 surveys ; 
4. Improvement in the quality of articular cartilage in the knee j oint as measured by T2 and T1rho relaxometry ; 
5. Days from day one of Study Medication intake to conversion to alternative therapy.  
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page36  
Additionally, we will review and discuss any possible correlation among secondary endpoint results.  
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page37 9.0 Study Population  
Male and female patients who present to the clinical practice s of the Principal Investigator  [INVESTIGATOR_54720] -Investigators will be enrolled if they 
meet all eligibility criteria.  Subjects from the community who self -identify in response to a flyer, newspaper advertisement, or website 
will be enrolled if they meet all eligibility criteria.  
 Enrollment Criteria    
9.1.1 Inclusion Criteria  
Subjects will be included if all of the following c riteria are met:  
1. Are male or female, ages 40 -80; 
2. Are willing to comply with all study related procedures and assessments;  
3. Are ambulatory as defined by [CONTACT_869910];  
4. Radiographic evidence of Kellgren -Lawrence grade II -IV osteoarthritis in one or both knees;  
5. Scores 4 -10 on the Numerical Rating Scale (NRS) for pain;  
6. Stable dose of screening/baseline medications for at least 2 months prior to the anticipated date of study drug dosing . 
 
9.1.2 Exclusion Criteria  
Subjects will be excluded if any of the following criteria are met:  
1. Females who are nursing, pregnant or planning to become pregnant during the duration of study drug dosing;  
2. Males who do not wish to abstain from sex or use contraceptive protection  during study drug dosing and for [ADDRESS_1214327] dose ; 
3. Subjects who do not have the capacity to consent themselves;  
4. Subjects who are unable to tolerate oral medication;  
5. Subjects having previously undergone any of the following treatments in the stated time  window : 
a. Surgery on the Study Knee in the past 6 months;  
b. Partial or complete joint replacement in the study knee. Partial or complete joint replacement in the 
contralateral knee is acceptable as long as the surgery was performed at least 6 months prior to enrollment 
and the operative knee is asymptomatic ; 
 
  
Clinical Protocol No. [ADDRESS_1214328] undergone arthroscopic surgery (including microfracture and meniscectomy) on the Study 
Knee in the last [ADDRESS_1214329] arthroscopic surger y on either 
knee at any time during the study period;  
d. Steroid injection, including extended -release corticosteroid (e.g., Zilretta®) within the last 5 months;  
e. Biologic (platelet -rich plasma, bone marrow, adipose tissue/cells) or hyaluronic acid injection into the Study 
Knee in the past 6 months;  
6. Subjects with any of the following drug/medication statuses:  
a. Currently taking Losartan;  
b. Opi[INVESTIGATOR_869871] 8 weeks and are not willing to discontinue these medications through the 
duration of the study;  
c. Senolytic agents taken within the past 6 months and are not willing to discontinue these medications through the 
duration of the study, including: Fisetin , Quercetin, Luteolin, Dasatinib, Pi[INVESTIGATOR_293119], or Navitoclax;  
d. Drugs that induce significant cellular stress and are not willing to discontinue these medications through the 
duration of the study, including alkylating agents, anthracyclines, platins, oth er chemotherapy drugs;  
e. Subjects taking the following other drugs if they cannot be held (per the Principal Investigator) for at least 
2 days before and during administration of Fisetin : cyclosporine, tacrolimus, repaglinide, and bosentan. ; 
7.   Subjects with any of the following disease statuses:  
a. Significant liver disease (i.e. greater than or equal to 2x the upper limit of normal bilirubin levels) or as in the 
opi[INVESTIGATOR_604051] I nvestigator;  
b. Significant renal disease (eGFR of <60 ml/min/1.73m2) or as in the opi[INVESTIGATOR_1237];  
c. History of other formally diagnosed joint diseases including, osteonecrosis, acromegaly, Paget's disease, 
Ehlers -Danlos Syndrome, Gaucher 's disease, Cushing’s syndrome, Stickler's syndrome, joint infection, 
hemophilia, hemochromatosis, or neuropathic arthropathy of any cause;  
d. Any active systemic autoimmune disease with musculoskeletal involvement or any history of systemic 
inflammatory arth ritis; 
e. Patients with type 1 or 2 diabetes (HbA1c > 6.5%) and/or taking medications that affect insulin levels, 
including: Metformin (within the last week), Glucocorticoids (within the last month), Acarbose (within the 
last week) ; 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page39 8.  Subjects unable to saf ely practically undergo an MRI (BMI > 40 kg/m2) or size exceeding limits of MRI equipment, implanted metal 
in study knee near joint surface, incompatible implant/device, severe claustrophobia;  
9.   Subjects that have any medical condition, including labora tory findings and findings in the medical history or in the pre -study 
assessments, that in the opi[INVESTIGATOR_684033] a risk or contraindication for participation in the study or  that could 
interfere with the study objectives, conduct or e valuation or prevent the patient from fully participating in all aspects of the study.  
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page40 10.0 Study Visits  
 
A full Study Schemata is provided in Section  23.1 of this document . 
 
Visit 1 ( Screening /Enrollment)  
 At the first patient visit, the following procedures will be performed:  
1. Full explanation of the clinical study, execution of Informed Consent, copy of signed informed consent sent home with patient;  
2. Subject will be assigned a deidentified study number;  
3. Vital signs;  
4. Medical and surgical history;  
5. Demographic information;  
6. Details of injury;  
7. Severity of injury;  
8. Medications;  
9. Physical exam with ROM of target limb;  
10. BMI;  
11. Urine pregnancy test for pre -menopausal women;  
12. Blood analysis;  
13. A radiograph of the target knee will be performed to confirm  the presence of Kellgren -Lawrence grade II -IV OA;  
14. The patients’ record will be reviewed, and the subject will be interviewed to determine if the eligibility  criteria are met ; 
15. Randomization.  
 
Patients who have met all eligibility criteria will be assigned, 1:1 via block randomization, to one of the two blinded study  groups.   
 
 Visit 2 ( Baseline ): (Within 3 months of Visit 1 ) 
Some procedures performed in this visit may be performed in Visit [ADDRESS_1214330] for Women of Child Bearing Potential (WOCBP)  
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page41 2. Quantitative MRI;  
3. Kinematic movement;  
4. Assessment of muscle strength, isokinetic dynamometry;  
5. Functional performance testing . 
 
After randomization is performed, a Study Team member will then inform the Vail Hospi[INVESTIGATOR_869872] ’s assigned 
randomization code,  and obtain  study medication . Subjects will take their first dose of study medication  at the clinic .  
 
Subjects  will be instructed to self -medicate for  day 2 followed by 28 days off.  A second course will be taken for two consecutive days 
(days 3 1 and 3 2).  
 
A Medication Log  recording medication administration will be provided  to the subject with instructions to co mplete during the period 
of administration.   
 
 Visit 3: Two Weeks after first dose of Fisetin or Placebo (+/ - 2 days ) 
All subjects will return to the study site 2-weeks  from the subject's last dose of Fisetin  or placebo. The following procedures will be 
performed:  
      1. Blood Analysis . 
 Visit 4: Two Weeks from  the Subject's Last Dose of Fisetin  or Placebo  (+/- 10 days ) 
All subjects will return to the study site two-weeks  from the subject's last dose of Fiset in (FIS) or placebo. The following procedures 
will be performed:  
1. Vital signs;  
2. Medical and s urgical history;  
3. Physical exam with ROM of target limb;  
4. Blood  analysis;  
5. Medications;  
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page42 6. Completion of augmented  PROs, including:  NRS , IKDC, Lysholm, TEGNER, WOMAC and SF -12; 
7. Protocol deviation assessment;  
8. Adverse event assessment.  
 
 Visit 5: Six Month s from  the Subject's First Dose of Fisetin  or Placebo (+/- 4 weeks)  
1. Vital signs;  
2. Medical and s urgical history;  
3. Physical exam with ROM of target limb(s);  
4. Blood  analysis;  
5. Completion of  augmented  PROs, including:  NRS, IKDC, Lysholm, TEGNER, WOMAC and SF -12; 
6. Medication s; 
7. Protocol deviation assessment;  
8. Adverse event assessment ; 
9. Quantitative MRI;  
10. Lower -extremity kinematic testing with video -motion analysis;  
11. Isokinetic  dynamometry testing;  
12. Functional performance testing . 
 
 Visit 6: [ADDRESS_1214331] Dose of Study Medication  (+/- 4 weeks)  
All procedures performed in Visit 5 will be repeated . 
 
 Additional Remote Follow -up 
In addition to the in -clinic follow -up visits above, the following remote follow -up will be                     conducted:  
 
10.6.[ADDRESS_1214332] Dose of Study Medication (+/- 4 weeks )  
Subjects will complete  the augmented PROs  electronically , including: NRS , IKDC, Lysholm, TEGNER, WOMAC and SF -12 
questionnaires .  
 
 Unscheduled Visits  and/or Subject Contact  
[CONTACT_869919](s) or subject contact [CONTACT_869920], all data must be documented in 
the appropriate study document  including the occurrence or adverse events and/or protocol de viations.  
 
10.8  Phone Calls  
Subjects will be contact[CONTACT_869921].  
 
 
 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page44 11.0 Study Tools  
 Vital Signs  (Visits 1, 3, 4, 5 , 6) 
Vital signs are to include measurement of temperature, blood pressure and heart rate.  
 Physical Exam : (Visits 1, 4, 5, 6) 
Physical exams are to include height, weight , ROM of the target limb , and general wellness check up to examine any adverse events.  
 Range of Motion (ROM) : (Visits 1, 4, 5, 6) 
Both the active and passive range of motion should be assessed. The normal knee extension is between 0 to 10 degrees. The nor mal 
knee flexion is between 130 to 150 degrees . Any pain, abnormal movement, or crepi[INVESTIGATOR_869873].  
 Blood  Laboratory Analysis : (Visits 1, 3, 4, 5, 6) 
Analyses in Column A will be performed by a CLIA -Certified Laboratory : 
Vail Health Laboratory .  
 
Analyses in Column B will be performed at the Steadman -Philippon Research Institute (SPRI)   
 
 
 
 
 
 
 
 
 
 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page45  
 
 
 
 
 
 
Column A  Column B  
CBC w/Diff  
CMP  
CRP  
 
 T-Cell Assay : Peripheral blood CD3+ T cell assay for P16INK4a: 30 
mL blood will be collected using EDTA tubes to measure p16 INK 
positive lymphocyte population in the peripheral blood - a biomarker 
of senescence and chronological aging. T-Cells will be enriched from 
whole blood using a commercial kit following manufactures 
instructions  (RosetteSep , Stem Cell Technologies #[ZIP_CODE]). P16 
expression will be measured by [CONTACT_937] -PCR using Taq -man primer -
probe system  from enriched T -cells.  
C12FDG Detection of Senescent Cells in Flo w: A portion of enriched 
T-cells collected from [ADDRESS_1214333] senescent cells using 
flow cytometry (Guava EasyCyte, Luminex).  
Biomarker Assessment for Senescent cells:  
Quantification  of Growth Factor and Cytokine/Chemokine 
Composition: The whole blood sample  will be pi[INVESTIGATOR_869874]® multiplex immunoassays (EMD 
Millipore Corp, Billerca, MA) that measure concentrations of growth 
factors, cytokines and chemo kines. Specific immunoassay kits (EMD 
Millipore Corp, Billerca, MA) a human cytokine/chemokine 
magnetic bead panel, TGF -β magnetic bead panel, MMP magnetic ESR 
Creatine Kinase  
Uric Acid  
 Vit D (25 hydroxy)  
Hb A1c  
 
 
 
 
 
 
 
 
 
 
  
Clinical Protocol No. [ADDRESS_1214334] 
manufacturer’s protocol for the Luminex® 200  (Luminex Corp, 
Austin, TX) multiplex instrument will be utilized as previously 
published (64). Plate will be analyzed with the Luminex® 200 
xPONENT 3.1 system (Luminex Corp, Austin, TX) using the 
xPonent® software (EMD Millipore Corp, Billerica, MA), whic h 
created a standard curve for each respective analyte utilizing a five -
parameter logistic curve -fitting method with the median fluorescent 
intensity. The proteins to be assayed include: sCD40L, EGF, Eotaxin, 
FGF-2, Flt -3, IFN -𝛂2, IFN -ɣ, IL-1𝛂, IL-1β, IL-1ra, IL -2, IL -3, IL -4, 
IL-5, IL -6, IL -7, IL -8, IL -9, IL -10, IL -12 (p40 and p70), IL -13, IL -
15, IL -17A, IP -10, MCP -1, MCP -3, MDC, MIP -1𝛂, MIP -1β, PDGF -
AA, PDGF -AB/BB, RANTES, TGF -𝛂, TNF -𝛂, TNF -β, VEGF, 
MMP (1,2,3,7,9,10,12,13), TGF -β (isoforms 1,2,3).  
 
Human enzyme -linked immunosorbent assay (ELISA) kits (R&D 
Systems) will be used to measure the following: Adipokines MMP -
degraded C -reactive protein (CRPM), MMP degraded type III 
collagen (C3M), cartilage oligomeric matrix protein (COMP), 
hyaluronic acid (HA), N -terminal propeptide of collagen IIA 
(PI[INVESTIGATOR_869875]), Col2 -3/[ADDRESS_1214335] of types I and II 
collagen, CTX -II, 4 -hydroxynonenal (4 -HNE), malondialdehyde 
(MDA), and 3 - nitro -tyrosine (3 -NT).   
 
 
 
 
 Patient Reported Outcomes (PROs) : (Visits 1, 2, 4, 5, 6) 
All PROs may be completed either on paper documents or by [CONTACT_869922] (Vroman 
Systems, Inc.).  Patients may complete questionnaires on a variety of electronic devices (personal computer, mobile phone, ta blet).   
  
PRO data to be collected include:  
Augmented Numerical Rating Scale (NRS) (visit 2 ): At baseline then once every [ADDRESS_1214336] 6 weeks of study medication 
treatment then once a week for an ADDITIONAL 6 weeks . 
 
IKDC, Lysholm, TEGNER, WOMAC and SF -12 (visit 2, visits 4, 5, and [ADDRESS_1214337] completion 
of medication ). 
 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page47 The Numerical Rating Scale  is a simple 0 -10 self -reported severity of pain scale, (zero being no pain and [ADDRESS_1214338] pain 
imaginable).  This  tool has been  validated to provide excellent test -retest reliability in assessing knee pain associated with OA31. The 
Steadman Philippon Research Institute has added several stand -alone questions that are administered with the questionnaire.  Only the 
validated portion, the simple NRS will be used to screen patients. In follow -up, each question will be analyzed individually. There is no 
composite score. A sample can be found i n Appendix C, Section 22.[ADDRESS_1214339] or receiving a disability pension because of knee problems.  It is simple to use, and it has been demonstrated to provi de 
acceptable psychometric performances as outcome measures for patients with a meniscal injury of the knee.  Like the Lysholm, it is 
recommended that it be used  in conjunction with other psychometric tools such as the SF 1232. 
 
The Western Ontario and MacMaster Universities (WOMAC) Osteoarthritis Index is a widely used self -administered health status 
measure assessing pain, stiffness, and function in patients with OA of the hip or knee. It has been demonstrated to fulfill c onvent ional 
criteria for face, content and construct validity, reliability, responsiveness and relative efficiency. It has been shown to be an excellent 
instrument for evaluative research in osteoarthritis clinical trials34. 
 
The SF -[ADDRESS_1214340] the SF -36 and has been shown to demonstrate the empi[INVESTIGATOR_869876] 12 -item short -form 
(SF-12) health survey summary measures and 8 -scale pr ofile in comparison with SF -36 summary measures and scales36. 
 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page48 
 Imaging Assessment of O A 
11.6.1  Radiographic Assessment : (Visit 1)  
Subjects will receive baseline radiographs of the knee( s). If a subject has had a satisfactory radiograph within the previous [ADDRESS_1214341] been employed to improve intra -articular visualization. Radiographs are used to evaluate osteophyte formation 
and joint space narrowing (JSN); grading schemes such as the Kellgren -Lawrence grading scheme37 and the Osteo arthritis Research 
Society International classification score establish guidelines for the diagnosis of OA progression37. 
 
11.6.2  Quantitative Magnetic Resonance Imaging ( MRI ): (Visits 2, 5, 6) 
Quantitative MRI will be performed at the Steadman clinic. In preparatio n for MRI, subjects will be asked to remove their shoes and 
any metal that may interfere with the scan (e.g. metallic clothing, jewelry) and will be provided with disposable, MRI -compatible 
clothing if needed.   
 
Images will be acquired on a 3T Siemens Mag netom Skyra -fit scanner.  
 
For the screening and follow -up MR scans, morphological T1 MR images will be acquired. These images provide evaluation of knee 
structure.  It is well known that structural alteration can lead to loss of collagen organization (e.g ., torn fibers and scar tissue) and changes 
in water content (e.g., dehydration).  
 
In addition, quantitative T2 MR images, which provide data on tissue MR signal relaxometry values, will be acquired to provid e 
information regarding cartilage health includi ng the relative level of water and collagen organization within the tissue.   
  
 
  
Clinical Protocol No. [ADDRESS_1214342] protected accounts.  The images will also be uploaded to the secure TSC PACS 
(Pi[INVESTIGATOR_869877]) for radiological assessment by a blinded radiologist.  Objective morphological 
measurements and Quantitative MRI value anal ysis will be performed from the DICOM files using Mimics, ImageJ, 3D Slicer, and 
MATLAB.  Specifically, the regions of interest will be segmented in either Mimics or 3D Slicer (equivalent function software)  and the 
masks will be exported to BPM format (bit map) and imported into MATLAB for extraction of T2 or T2 values within the regions of 
interest. Morphological measurements may be taken in either Mimics, ImageJ, or 3D Slicer depending upon software scheduling 
coordination.  All of these programs perform e quivalently for this purpose.  Results will be output to an Excel spreadsheet for statistical 
analysis.  
 Functional Performance Testing : (Visits 2, 5, 6) 
Measures of functional performance will include [ADDRESS_1214343] (6MW), timed -up-and-go test (TUG), and 4 -meter walk (4mW) tests38-
40.  The 6MW test measures the distance walked in [ADDRESS_1214344] reliability, with intra -class  correlation coefficients from 0.95 -0.97, and a low coefficient of variation (10.4%)41,42. 
The 6MW test is safe, easy to administer, well tolerated, and does not require ex tensive patient training38-40.  
 
The timed up and go TUG measure s the time it takes a patient to rise from an arm chair (seat height of 46 cm), walk [ADDRESS_1214345] has excellent re liability as measured in a group of 60 functionally 
disabled older adults (mean age 80 years)43. The 4MW will be assessed at the fastest safe speed for each participant. This test assesses 
the capacity for performance of certain activities (e.g. crossing a street before the light changes).   The time it takes for eac h participant 
to ascend and descend [ADDRESS_1214346] risk of physical disability, higher health care utilization and incr eased 
mortality44-46. It has been established as a meaningful outcome measure in older pers ons with a wide range of conditions47-49. 
Additionally, it is a valid and reliable measure50-52; and is well tolerated by [CONTACT_869923]53,54. 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page50 
 Lower -Extremity Kinematics, Video -Motion Analysis :                                 (Visits 2, 5 , 6) 
Video -motion analysis can assess even subtle changes in musculoskeletal function due to limited joint range of motion, stiffness, p ain 
and/or we akness.  Subjects will be equipped with a full -body retro -reflective marker set (including four -marker thigh and shank clusters 
on each leg).  Kinematics measurements will be captured with a video -motion analysis system consisting of 18 infrared, 12-megapi [INVESTIGATOR_869878] (Oqus 7, Qualisys AB, Gothenburg, Sweden).  Ground reaction forces will be acquired simultaneously using 
an instrumented treadmill or force plates (Bertec, Columbus, OH).  Angular kinematics and net joint moments will be determin ed for 
the trunk, pelvis, hips, knees and ankles using Visual3D software (C -Motion, Inc., Germantown, MD). Tasks will include treadmill gait 
(1 m/s) and a 4 -step stair ascent/descent.  
 Assessment of Muscle Strength, Isokinetic Dynamometry:                                  (Visits 2, 5 , 6)                                                                
The isokinetic muscle test will involve the use of the HUMAC NORM Isokinetic testing system (Computer Sports Medicine Inc,  
Stoughton, MA)55.  Participants will sit in the chair and press their leg against a padded bar as hard as they can while moving their leg 
back and forth (flexing and extending).   They will do this at one speed (60°/s) with three repetitions at each speed for both the left and 
right leg. This will allow measurement of muscle activity surrounding the knee joint and the amount of force they can produce.  
Participants will  be given a warm -up period (5 minutes walking or cycling), practice trials, and adequate rest time between repetitions 
(30 sec) and between left/right sides (5 min).  As is standard practice when using the HUMAC NORM  system, padded straps will be 
used on t he participant's torso and legs in order to isolate the lower leg movements and reduce the contribution of other muscles.  All 
measurements will be normalized to % body weight.  
 
 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page51 12.0 Study Management of Adverse Events  
 Definition  
An adverse event (AE) is any u ntoward medical occurrence in a subject administered a Study Medication and which does not necessarily 
have a causal relationship with this treatment.  An AE can therefore be any unfavorable and unintended sign (including an abn ormal 
laboratory finding), s ymptom, or disease temporally associated with the use of whether or not related to the Study Medication (ICH E2A 
II/A/1, 21 C FR 312.32).  
 
All pre -existing medical conditions will be recorded on the medical history study document. Starting with the administration of the 
Study Medication any new experience that was not present at baseline or  worsening of an event present at baseline in intensi ty or 
frequency, is considered an adverse event.   
 
Note: U nchanged, chronic conditions are NOT adverse events and should not be recorded .  
 
It is recognized that subjects will exhibit (throughout follow -up) symptoms of the underlying disease process of th at fluctuates in severity 
and duration.   
 
Adverse events will include those occurrences, which when compared to before treatment meets any of the following criteria:  
 
• Represent a new event or escalation of an event ;  
• Require a new escalation in  treatment ; 
• Lasts longer ; 
• Experienced more frequently ; 
• More intense ; 
• Different in character ( e.g. stabbing vs. ache) ; 
• Experienced in a different part of the body ; and/or  
• Brought on by [CONTACT_869924] . 
 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page52 
 Recording Adverse Events  
Adverse event s that occur during Study Medication administration will be recorded.  Terms should be recorded consistently, using 
acceptable medical terms.  When possible, a diagnosis should be identified as the AE (i.e., disease or syndrome) rather than the 
component signs and symptoms, and recorded on the case report form (e.g., record congestive heart failure rather than dyspnea , rales 
and cyanosis).  However, signs and symptoms considered unrelated to encountered syndromes or diseases are to be re corded as 
individual AEs (e.g., if congestive heart failure and severe headaches are observed at the same time, each experience is to be recorded 
as an individual AE).  The AE should not be recorded as a procedure or clinical measurement (i.e., a laborator y or vital sign) but should 
reflect the reason for the procedure or diagnosis.  
 
Death is considered to be an outcome of an AE.  The cause of death (rather than the term “death”) should be recorded on the serious AE 
and death report case report forms.   
 
Subjects should be encouraged to report AEs spontaneously or in response to general, non -directed questioning.  At each required visit 
(or whenever reported) during the study, all AEs that have occurred since the previous visit must be recorded on the AE case report 
form.   
 
All AEs, regardless of seriousness, severity, or presumed relationship to the treatment must be recorded using medical termin ology .  
 
All AEs must be followed until resolution or until a stable clinical endpoint is reached.  All measures required for AE manag ement and 
the ultimate outcome of the AE must be recorded in the study  document .  All adverse events that occur in the study popul ation will be 
tabulated and summarized.  
12.2.[ADDRESS_1214347] and/or  the 
Study Team .  This may be unknown if at the end of the study the event is not resolved.   In this case, the event  will be indicated to be 
unresolved.  
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page53 12.2.2  Incidence  
An AE may be classified as “intermittent” or  “continuous if has no periods o f abatement.  
12.2.3  Relationship to  Study Medication   
The Principal Investigator  [INVESTIGATOR_869879] a reasonable possibility that the Study Medication  caused or contributed 
to an AE.  
 
Many terms and scales are used to describe the degree of causality between a  Study Medication  and an event.  The expression “reasonable  
causal relationship” is meant to convey in general that there are facts (evidence) or arguments to suggest a causal relations hip (ICH 
E2A, III/A/1).  
Determination of whether there is a reasonable possibility that a treatment caused or contributed to an AE  includes assessing temporal 
relationships, biologic plausibility, association (or lack of association) with underlying disease, and presence (or absence)  of a more 
likely cause.  
 
As is recommended in FDA draft guidance document, Safety Reporting Requireme nts for INDs and BA/BE Studies (2010) , we define 
four degrees of relatedness: “unrela ted”, “probably not related”, “ suspected adverse drug reaction ” (SADR) or “adverse reaction”.  
 
Unrelated (clearly not related to the research)  
The occurrence of the AE is not reasonably related in time, OR the AE is considered unlikely to be related to the treatment ( biologically 
implausible).  
 
Probably not related (doubtfully related to the research)  
The administration of the treatment and the AE are not considered reason ably related in time AND the AE could also be explained by 
[CONTACT_869925] (concurrent illness/underlying disease, other drugs or procedures).  
 
Suspected Adverse Drug Reaction (SADR )  
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page54 Suspected adverse reaction means any AE for which there  is a reasonable possibility that the treatment caused the AE.  A ‘reasonable 
possibility’ means there is evidence to suggest a causal relationship between the treatment and the AE.  A SADR  reaction implies a 
lesser degree of certainty about causality than  adverse reaction, which means any AE caused by a treatment.  
The Principal I nvestigator should consider if exposure to the treatment and the AE are reasonably related in time AND the treatment is 
more likely than other causes to be responsible for the AE or  is the most likely cause of the AE. 
 
Adverse Reaction  
An adverse reaction means any adverse event caused by a drug.  Adverse reactions are a subset of all suspected adverse reactions for 
which there is reason to conclude that the treatment caused the event.  
 
If the event is felt by [CONTACT_869926] a SADR or an adverse reaction, every effort will be made to identify the 
event as related to the Study Medication .  Adverse events that are generally felt to be attributable to the Study Medication occur in close 
temporal relationship to the onset of dosing. A discussion of  AEs that are common with the Study Medication  is found in the Section 
13.0 of this  document .  
All adverse reactions and SADRs will be followed until resolution or the Investigator judges the experience to be chronic or stable.  
12.2.4  Severity (Intensity) of Adverse Events  
The severity of the adverse events should be assessed based on the following grading scale:  
• Grade 1 (Mild): A dverse event that is noticeable to the subject and may require additional therapy;  
• Grade 2 (Moderate): Adverse event that interferes with the subject’s activities and requires inter vention or additional therapi[INVESTIGATOR_014];  
• Grade 3 (Severe) : Adverse event that is intolerable, or necessitates additional therapy or places the subject at immediate risk of 
harm ; 
• Grade 4: A dverse event that is life ‐threatening or disabling ( hospi[INVESTIGATOR_059]) ; 
• Grade 5: Adverse event that results in Death . 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page55 12.2.5  Expected and Unexpected Adverse Events  
“Expected” AEs are those that have been previously reported as associated with the disease process .  In addition, adverse events 
associated documented potential risk identified in Section  13.0 of this protocol will be noted as “Expected”. All others are to be recorded 
as “Unexpected”.   
12.2.6  Serious Adverse Events  
An AE or suspected adverse reaction is considered “serious” if, in the view of either the Principal I nvestigator , it results in any of the 
following outcomes:  
• Death;  
• A life -threatenin g adverse event ; 
• Hospi[INVESTIGATOR_059] ;  
• Disability or permanent damage ; 
• Congenital anomaly/birth defect ; 
• Other serious  event s that  may jeopardize the patient and may require medical or surgical intervention (treatment) to prevent one 
of the other outcomes . 
An AE or suspected adverse reaction is considered “life -threatening” if, (in the view of the Principal Investigator)  its occurrence places 
the patient or subject at immediate risk of death.  It does not include an AE or suspected adverse reaction that, had it occurred in a more 
severe form, might have caused death.   
 
Serious and/or unexpected adverse event (s) may prese nt as either a local or systemic response, or both, which may present as an 
anaphylactic response associated with generalized urticaria, shortness of breath, or respi[INVESTIGATOR_869880].  
 
Subjects will be instructed to contact [CONTACT_869927] a systemic reaction occurs between scheduled study visits.  Subjects 
may be assessed initially over the phone and may be asked to return to the study site for an additional visit to assess the r eaction.  
 
  
Clinical Protocol No. [ADDRESS_1214348]. If managing adverse events requires unblinding to the any member 
of the Study Team, the appropriate team member will disclose the group identity to the necessary medical provider.  
 
The IRB will be noti fied of unanticipated and serious adverse events within 5 business days of identification.  This reporting may come 
from the Study Team, the Independent Medical Monitor, or both.  
Investigator Sponsor will notify FDA in an IND safety report (Form 3500A), u nexpected fatal or life threatening suspected adverse 
reactions where there is evidence to suggest a causal relationship between the Study Medication and the adverse event will be  reported 
as a serious suspected adverse reaction.  This will be reported to the FDA no later than 7 calendar days after the sponsor -investigator’s 
initial receipt of the information about the event.  
Other unexpected serious suspected adverse reactions , where there is evidence to suggest a causal relationship between the Study 
Medication  and the adverse event, will be reported as a serious suspected adverse reaction.  This will be reported to the FDA on FDA 
Form 3500A no later than 15 calendar days after the sponsor -investigator’s initial receipt of the information.  
 
The sponsor m ust identify all IND safety reports previously submitted to FDA concerning a similar suspected adverse reaction and  must 
analyze the significance of the suspected adverse reaction in light of previous, similar reports or any other relevant inform ation.  
 
  
Clinical Protocol No. [ADDRESS_1214349] s in this study include all those currently associated with  osteoarthritis (OA) of the knee and its progression.  
Additional risk to subjects which might arise as the result of study participation are discussed below .  
 Associated with Fisetin Administration  
Based upon the review of the published literature , pre-clinical data  and available clinical data , we do not anticipate the occurrence of 
serious adverse events related to the prescribed regimen of Fisetin ( FIS) in this study.  However, potential  side effects include the 
following : 
• Reduced appetite,  
• Altered activity,  
• Nausea,  
• Dry mouth,  
• Diarrhea,  
• Vom iting,  
• Fatigue . 
• There have been positive findings with Fisetin in the Ames and micronucleus assays.  
 
 
In addition, FIS has been demonstrated to have inhibitory activity of cytochrome P450, and to have adverse interaction with caffeine, 
tobacco/nicotine con sumption for which we have established exclusion criteria .  These are listed in detail in  Section  9.1.[ADDRESS_1214350] of possi ble drug interactions with FIS are provided in Section   22.4, Appendix D  of this document.  
 Risk Associated with Placebo Administration  
If results of this study reveal that administration of FIS improves OA symptoms and/or joint structure, subjects random ized to placebo 
may miss these benefit(s).   
 
  
Clinical Protocol No. [ADDRESS_1214351] only a 50% chance of being randomized to receive  FIS. In addition, subjects will be 
told that the advantages of receiving FIS in the treatment of OA in humans are unknown . 
 Associated with MRI  
The MRI scan involves exposure to loud noise and  positioning in a small space.   Subjects may feel claustrophobic, fatigued or nauseated 
especially if they are uncomfortable with tight spaces.  The MRI scan does not involve t he use of x -rays or injectable dyes. There are no 
known reports of increased cancer or birth defects associated with this procedure.  The MRI scan exposes the subject to high magnetic 
fields, which can be dangerous for those with pacemakers and some metal implants.   
 
All subjects will be carefully screened for potential contraindications for MRI.   Subjects will be provided with hearing protection and 
may listen to their choice of streamed music for comfort. MRI -compatible padding and/or blankets may be used as requested for subject 
comfort. Subjects will be provided with a ‘squeeze ball’ activated  microphone to allow communication with the MRI technologists so 
that they can notify the technologist of any problems or the desire or need to abort the scan.  
 Associated with PRO Questionnaires  
The completion of numerous PRO questionnaires can be laboriou s and uncomfortable presenting a potential risk of emotional distress.  
 
Whenever possible PRO questionnaires will be completed remotely through electronic link in order to minimize time needed to c omplete 
questionnaires.   The subject will be told that he/she may discontinue questionnaire  completion at any time if the questionnaire causes 
emotional distress.   
 Associated with  Physical Exam  
There is a potential risk of pain and/or discomfort.  Palpation and low -magnitude manu al force applied to the knee could result in mild 
to moderate discomfort, depending upon a subject's subjective perception of discomfort and knee condition.  
 
Care will be taken to limit this discomfort to not exceed that experienced during normal daily ac tivities such as walking, climbing stairs, 
putting on shoes, etc.   Only experienced, trained clinicians will perform the exam , and the exam will be modified if the subject indicates 
 
  
Clinical Protocol No. [ADDRESS_1214352] a padded bar, skin irritation (including reddening and itchiness) from the stra ps, and 
general joint discomfort from isolat ing the knee joint.  
 
Subjects will be informed of this possibility as well as their option to take rest periods and/or discontinue isokinetic musc le strength 
testing at any time during the evaluation.  All participants will be given a warm -up period.  The b ar and straps will be positioned as 
comfortably as possible for each participant.  
 Associated with  Motion Capture  
There is a small risk of skin irritation from the tape used to attach the reflective markers.  The tasks performed during motion capture 
are ac tivities of daily living and therefore would place the participants at minimal risk for additional injury.   
 
If skin irritation occurs, they will be instructed to apply over -the-counter anti -inflammatory creams, ointment or spray of their choice  to 
the sk in.  In addition , to avoid injury subjects will be coached to take  rest periods if needed and/or discontinue motion  at any time during 
the evaluation . 
 
  
Clinical Protocol No. [ADDRESS_1214353]’s Private Health Information could be accidentally breached during the research process.  Many system wide safety  
guards are in place to prevent this occurrence , including:  
Subject de -Identification , Badge -access, locked offices ; controlled  access to research offices and documents , password protected work 
stations and password complexity enforced;  state-of-the-art and promptly updated firewall to block external web traffic;  end-to-end 
encryption on all connections , automatic email encryption system for all outbound (off TSC server) email , Electronically secure online 
questionnaire access.  
 Risk Analysis  
 The Study Team will perform regular review of cumulative adverse events and will modify mitigation strategy as neces sary.  Baseline 
risk analysis is shown in Table [ADDRESS_1214354] to greater and more 
frequent scrutiny and discussion of mitigation.  As the study progresses , modifications to this analys is will be fully document and 
retained.  
 
Table 1 3.11 Risk Analysis  
 
Risk   
Likelihood  
of  
Occurrence  
1= not likely  
2= possible  
3= very likely   
Potential Impact on 
Subject Safety  
1=little    
2= moderate  
3= severe   
Detectability  
 
 
1= high  
2= moderate  
3= low   
Overall Risk Score  
(Hierarchy of assessment and 
follow -up) 
 
(3-9) 
Associated with F IS Administration  2 3 2 7 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page61 Associated with Placebo Administration  1 1 3 5 
Associated with MRI  2 1 1 4 
Associated With PRO Questionnaires  2 1 1 4 
Associated With Physical Exam  2 1 1 4 
Associated With Blood Draw  2 2 1 5 
Associated With Isokinetic Muscle Strength Testing  2 1 1 4 
Associated with Functional Performance Testing  2 1 1 4 
Associated With Motion Capture  2 1 1 4 
Associated with Breach of Confidentiality  2 2 2 6 
 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page62 14.0 Stoppi[INVESTIGATOR_1869]/Termination of Study Enrollment  
The triggering of stoppi[INVESTIGATOR_869881] , subject dosing  and notification of the 
Medical Monitor  and IRBs.  Although dosing and enrollment will cease, all subjects currently taking or have completed Study 
Medication treatment up until that point will be followed according to the protocol for the occurrence of a dverse events.  Efficacy follow -
up will be continued only if , in the Principal Investigators judgment, efficacy follow -up would be clinically meaningful.  Subject dosing 
and e nrollment will be reconvened only when permission is granted by [CONTACT_1201].  
 
 Termina tion of Enrollment by [CONTACT_079]  
[INVESTIGATOR_869882].  
1. Any unexpected serious or life-threatening  AE that cannot be determined to be unrelated to Study Medic ation ; 
2. It is determined that the protocol precipi[INVESTIGATOR_869883]-compliance issues beyond reasonably missed follow -up. 
 
 Termination of Enrollment by  [CONTACT_869928].  
 
 Removal of Subjects from  the Study  
Principal Investigators may remove a subject from the study if: 
1. A subject demonstrates poor compliance with study protocol;  
2. There is concurrent illness or required medical treatment that interfere s with study assessments;  
3. The Principal Investigator [INVESTIGATOR_869884]’s health, safety or welfare is at risk . 
 Withdrawal of Consent  
Subject may withdraw their consent to participate in the Study at any  time, for any reason.  
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page63 15.0  Statistical Considerations  
 Study Overview, Aims and Objectives  
The aim of this study is to perform a single -center randomized clinical trial (RCT) to test whether the dietary supplement Fisetin (FIS)  
can improve symptoms, kinematic function and soft tissue quality in patients with knee osteoarthritis.  The proposed th erapeutic systemic 
mechanism of FIS in this population is by [CONTACT_869929] -
related disease, including osteoarthritis (OA).  
 
Assessments occur over 18 months following enrollment, an d include safety monitoring, biomarker assessment, kinematic testing, 
quantitative MRI , knee -related patient reported outcomes, and observation of conversion to alternative treatment modalities.  We 
hypothesize that the FIS treated group will not experienc e adverse events at a higher rate than the placebo group.  Additionally, we 
hypothesize that improved OA disease status will be observed among the several pain, function and tissue quality endpoints fo r the FIS 
group when compared to the placebo group.  
 Study Design  
The study will follow a two -arm, double -blind, placebo -controlled approach.  Allocation will be 1:[ADDRESS_1214355] and/or data 
analysis will remain blinded throughout the study period.   
 Randomization  
To better ensure equivalent group sizes in the event of unenrollment or loss -to-follow -up, a block randomization scheme will be 
followed with block size of n=8.  The f ollowing steps will be adhered to when enrolling a subject into one of the two study arms:  
1. Eight tokens, numbered 1 -8, will be held in a jar stored in the study manager’s office within T SC and S PRI. 
2. Upon enrollment, a token will be drawn from the jar, and not replaced back into the jar.  
3. The Block Number and Within -Block Number will be recorded by [CONTACT_64839] a blinded version of the 
Enrollment/Randomization log.  
4. The Block Number and Within -Block Number will be disclosed to the Vail  Health Hospi[INVESTIGATOR_869885]/Randomization log.  
 
  
Clinical Protocol No. [ADDRESS_1214356] and the new block.  
 
 
 
Figure 15.3  Portion of the randomization/enrollment log demonstrating group allocation 
for subjects enrolled into block #1.  
Block  
Number  Within -Block  
Number  Group (Randomization not finalized, for illustration only)  Subject ID  
Number  Patient  
ID Enrollment  
Date  
[ADDRESS_1214357] for differences in baseline covariates between groups.  
 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page65 Whenever applicable, assessment of endpoints that are measured at serial time points will be analyzed using methods that account for 
this repeated measure structure.  Listwise deletion in response to missing data points and categorization/dichotomization of continuous 
measurements will be avoided to every extent possible.  
 
Summary statistics will be reported as group medians with quartiles or extrema.  Meanwhile estimates calculated for statistical inference 
will be reported with (1 -α)% confidence intervals.  Model fit and satisfactorily meeting model assumptions will be assessed for all 
multivaria ble regression and linear mixed -effects models using residual analysis.  
 
The Statistical Computing Language R will be used to produce all analyses and plots.  
   Endpoints  
15.5.[ADDRESS_1214358] independently.  When comparing the two treatment groups, dichotomous (yes/no) endpoints will be assessed for asso ciation 
using Fisher’s exact test.  Adverse events and symptoms that may occur multiple times in a single subject will be analyzed as count 
variables , and group differences will be assessed using simple Poisson regression or simple negative binomial regression.  
 
This is a small Phase I/II trial in which to  assess safety, thus we will report all safety data thoroughly and aim to liberally identify 
potential side -effects and risks that may warrant close study in future, larger trials.  No adjustments will be made for multiple 
comparisons in this set of safety  endpoints.  
 
15.5.2  Secondary Endpoints  
 
[IP_ADDRESS]  Imaging Assessment of O A 
 
 
  
Clinical Protocol No. [ADDRESS_1214359] to 1 2 months as well.  
 
Secondarily, multiva riable modeling techniques such as support vector machines (SVM) and/or principal components analysis (PCA) 
will be pursued to characterize the SASP response profile that distinguishes the FIS and placebo groups.  
[IP_ADDRESS]  Kinematic, Strength and Functional Performa nce Testing  
Measurements from the timed -up-and-go test (TUG), [ADDRESS_1214360]  (4mW) , 6-minute walk test  (6MW) , time to descend [ADDRESS_1214361] (SCT) , video motion capture of lower -extremity kinematics, and isokinetic muscle test using the HUMAC NORM  system will be 
assessed as continuous variables. Previous testing has identified these measurements follow a relatively Gaussian distributio n, so 
parametric comparison of means (Welch’s t -test) is planned between treatment groups.    
 
[IP_ADDRESS]  Pain and P RO Assessment  
 
The hypothesis in this study is that FIS will induce a systemic anti -inflammatory and senolytic effect, thereby [CONTACT_869930] -reported function and quality of life compared to the placebo group.  Early subjective assessment (every [ADDRESS_1214362] dose of study medication and once weekly for the following 6 weeks)  will be limited to a short augmented 
numerical rating scale questionnaire.  Linear mixed -effect random -intercepts modeling with will be used t o characterize the trend in 
self-reported pain over [ADDRESS_1214363]’s 
baseline PROM value used as a covariate.  Among the 4 postoperative time -points for assessing these validated  PROMs, the Holm -
Bonferroni method will be used to control the family -wise type -1 error rate to 0.05 within each PROM scale tested.  No multiplicity 
adjustments will be made across different PROMs, which are commonly highly intercorrelated.  
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page67 [IP_ADDRESS]  Conversion to Secondary Interventions  
In important endpoint for subjects enrolled in this study will be conversion to alternative treatments.  The protocol allows for a single 
intra-articular corticosteroid injection into the knee to manage knee pain without necessitatin g removal of the subject from the study.  
However , if a study  subjects  elects to convert to a regenerative medicine treatment (e.g.  platelet rich plasma or bone marrow aspi[INVESTIGATOR_421024]) or a surgical intervention (e.g. microfracture or total joint replacement) , they will be removed from the study . Cox 
proportional hazards regression will be performed to compare the hazard rate of conversion to each of these two treatment categories 
between treatment groups.  
 
                Statistical Power and Sample Size  
Anticipated effect sizes for the group difference with respect to MRI -assessed cartilage quality were derived from the literatu re, however 
a paucity of literature was found in the knee OA literature when comparing various grades of advanced osteoarthritis. As a si mplifying 
assumption, we derived an anticipated effect size for clinically meaningful change in T1rho values from a rec ent meta -analysis (MacKay, 
et al, 2018, J Osteoarthritis and Cartilage) that reported the standardized mean difference (SMD) between mild OA and healthy  controls.  
 
We aim to power this study to detect an effect size between the FIS and placebo treatment g roups that is equal to the meta -analyzed 
effect size described above (SDM=0.73). The statistical method for this unadjusted, independent groups comparison of means, a nd the 
significance level will be set at α=0.05.  Assuming 2 -tailed testing and requiring 80% statistical power, [ADDRESS_1214364]. Anticipating a 20% drop -out or incomplete follow -up rate, we aim to enroll no more than 
100 total OA patients (30 per groups, and 6 per group to account for 20% drop out). Power calculations were performed using G*Power 
(version 3.1; Universität Düsseldorf).  
                Missing Data  
Whenever possible, statistical methods such as linear mixed -effects modeling which naturally handle missing data will be utili zed.  
Missing data will be investigated carefully by [CONTACT_46134], the study manager and the clinical staff to assess its pr obable cause, 
and whether missing not at random (MNAR, missingness dependent on outcome), missing at random (MAR, missingness  not dependent 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page68 on outcome but can be fully accounted for by [CONTACT_650964] -missing covariates) or missing completely at random (MCAR, missingness 
independent of both observed variables and unobserved parameters of interest) is most likely.   
 
If any missing dat a patterns are determined to be MNAR, this observance will be reported narratively in the final report(s) and 
publication(s), and no imputation methods will be pursued.  Little’s test will be used to assess whether missing values are m issing 
completely at random (MCAR)  For methods that require complete data or listwise deletion (e.g. PCA), and where missing data is 
determined to be reasonably missing at random (MAR or MCAR), multiple imputation using predictive mean matching will be 
employed.  
                Data Preparation and Maintenance of Blinding  
The study manager will direct the data compi[INVESTIGATOR_869886].  Gathering of partial midpoint data will be performed at reporting mi lestones throughout the study, but no statistical 
inference testing will be conducted until study completion.  Research scientists, engineers, clinicians and database managers  will 
assemble their respective data spreadsheet using the patient ID number and will remain blinded to treatment group allocation throughout 
this process.  As a final step before data analysis, group allocation will be added to the research spreadsheets, but this wi ll be limited to 
“Group A” and “Group B”.  The full statistical analys is will be performed prior to unblinding which group received the FIS supplement.  
 
 
 
 
 
 
 
 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page69 16.0 Principal Investigator’s Ethical and Regulatory Obligations  
 
The Principal Investigator [INVESTIGATOR_869887], the study 
protocol  and applicable regulations; for protecting the rights, safety, and welfare of subjects under the investigator's care; an d for the 
control of the Study Medication .  The Principal Investigator [INVESTIGATOR_869888]  (FIS)  or 
placebo,  is administered.  A discussion of the Principal Investigator’s minimal responsibilities follows.  
 
 Study Conduct: Ethics and Good Clinical Practice  
Principal Investigator [INVESTIGATOR_869889] a n 
appropriate Study Team designee  responsible to the Principal Investigator.   
 
This study must be carried out in compliance with the protocol and in accordance with the Good Clinical Practice, ICH Guideli nes and 
the Declaration of Helsinki, concerning medical research in humans (Recommendations Guiding Physicians in B iomedical Research 
Involving Human Subjects, Helsinki 1964, amended Tokyo 1975, Venice 1983, Hong Kong 1989, Somerset West 1996).   
 
The Principal Investigator [CONTACT_416326] s, when signing the protocol, to adhere to the instructions and procedures described in it and thereby [CONTACT_869931].  
 Institutional Review Board  
The Principal Investigator [INVESTIGATOR_869890].  The Principal Investigator [INVESTIGATOR_869891].  Except when the changes constitute minor administrative ones or where necessary to eliminate apparent im mediate 
hazards to human subjects, the Principal I nvestigator will not  make any changes in the research without IRB approval.  
 
Before implementing this study, the protocol, the proposed informed consent form and other subject  information, must be reviewed and 
approved by [CONTACT_4707] (IRB).  
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page70  
Other Principa l Investigator responsibilities relative to the IRB include the following:  
• Submit all protocol a mendments to the IRB for review;  
• Report to the IRB any information about serious AEs reported in other studies associated with treatment ; 
• Provide the IRB with a ny other information it requests before or during the conduct of the study;  
• Report to the IRB all adverse events as required by [CONTACT_869932](s);  
• Maintain a file o f IRB/study -related information;  
• Update the IRB  on a minimum of a yearly basis;  
• Maintain IRB approval during the duration of the study.  
 
 Informed Consent  
Principal Investigators must explain to each subject  the nature of the study, its purpose, the procedures involved, the expected duration, 
the potential risks and benefits involved and any discomfort it may entail.  Each subject  must be informed that participation in the study 
is voluntary and that he or sh e may withdraw from the study at any time and that withdrawal of consent will not affect his or her 
subsequent medical treatment or relationship with the treating physician.  
 
This informed consent should be given by [CONTACT_3553] a standard written statement, w ritten in non -technical language.  The subject should 
read and consider the statement before signing and dating it and  should be given a copy of the signed document.  
 
No subject  can enter the study before  his/her informed consent has been obtained.  
 
The Informed Consent Form must be submitted by [CONTACT_079] [INVESTIGATOR_869892].  
  
 
  
Clinical Protocol No. [ADDRESS_1214365] be made only by [CONTACT_869933] /or other site trained personnel. Training will be documented and 
logged in the site study binder.  
 
16.4.1  Study Medication  Accountability  
It is the responsibility of the Principal Investigator [INVESTIGATOR_869893] .  This accounting is to be recorded in appropriate documents kept at the clinical site.    
 
16.4.2  Study Documents  
The investigator/institution should maintain adequate and accurate source documents and trial records that include all pertinent 
observations on each of the site's trial subjects. Source data should be attributable, legible, contemporaneous, original, ac curate , and 
complete. Changes to source data should be traceable, should not obscure the original entry, and should be explained if neces sary (e.g., 
via an audit trail).  
 
16.4.[ADDRESS_1214366] retain Essential Study Documents including: protocols, amendments, IRB/EC approvals, signed and 
dated consent forms, source documents, medical records, case report forms, device accountability records, all correspondence and all 
other documents pertaining to the conduct of the study . 
 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page72 16.4.4  Records/Reports Inspection  
Investigator sites and study documentation may be subject to Quality Assurance (QA) audits during the course of the study.  I n addition, 
inspections may be conducted by [CONTACT_48699], during and after study c ompletion.  
 
The Investigator agrees to allow inspectors from regulatory agencies to have access to all study records, including subject s ource 
documents.  By [CONTACT_4907], the Investigators agree to these requirements and will assist the ins pectors in their duties. The 
Investigator should immediately notify the Sponsor of an upcoming inspection.  
 
Investigators shall upon request from any properly authorized officer or employee of FDA, at reasonable times, permit such of ficer or 
employee to ha ve access to, and copy and verify any records or reports made by [CONTACT_869934] 312.62.  The 
Investigator is not required to divulge subject names unless the records of particular individuals require a more detailed st udy of the 
cases, or  unless there is reason to believe that the records do not represent actual case studies, or do not represent actual results o btained.  
 
16.4.5  Study Oversight  
The investigator is responsible for supervising any individual or party to whom the Principal I nvestigat or delegates trial -related duties 
and functions conducted at the trial site.  
 
 If the investigator/institution retains the services of any individual or party to perform trial -related duties and functions, the 
investigator/institution will ensure this indi vidual or party is qualified to perform those trial -related duties and functions and will 
implement procedures to ensure the integrity of the trial -related duties and functions performed and any data generated.  
 
16.4.[ADDRESS_1214367] safety. The study monitoring program will apply a risked - based approach to 
ensure that:  
 
1. All treatment emergent adverse events are accurately recorded;  
2. The rights and well -being of the human subjects are being protected;  
3. The reported data are accurate, complete, and verifiable from source documents;  
4. The conduct of the study complies with the currently approved protocol and any amendments, and in accordance with all local, 
state and/or federal regulatory agency requirements and good clinical practice ( GCP ) guidelines.  
 
During the course of the study, monitoring  visits will be conducted according to a written Monitoring Plan.  The Investigator must 
provide allocate sufficient ti me for the monitor to inspect subject medical records, source documents, case report forms, Study 
Medication  accountability records, and regulatory documents.   
 
Key trial personnel must be available to assist th e monitor.  Although the Principal Investigat or must give monitors  access to relevant 
hospi[INVESTIGATOR_893], to confirm their consistency with the CRF entries , no information in these records about the identity of the 
subjects will leave the study site.  Monitoring standards require full verif ication for the presence of informed consent, adherence to the 
inclusion/exclusion criteria, and documentation of all AEs, SAEs and the recording of efficacy and safety variables.   
 
Checks  of the consistency of the source data with the CRFs are performed according to the study specific Monitoring Plan.  Monitoring 
Reports will include a summary of what the monitor reviewed as well as complications, significant findings, deviations and de ficiencies, 
conclusions, and actions taken or to be taken to ensure site compliance.   
 
A Study Monitoring Plan will be submitted to FDA prior to the first subject treated.  
 
 
  
Clinical Protocol No. [ADDRESS_1214368] the office and return for his/her evaluation.  If a returned 
letter receipt or an undeliverable response is received, this notice will be retained in the subject’s study binder that will  note the subject 
is lost to follow -up.  If the study subject wishes to withdraw from the study, the reason(s) for discontinuation will be recorded in the 
subject’s chart and on the appropriate CRF, if the subject gives a reason.  If a significant symptom or adverse event is as sociated with 
discontinuation, this will be recorded on the CRF as well.  
 Data Management  
Data is to be managed in accordance with a written Data Management Plan which is to be retained as described in  Section  16.4.[ADDRESS_1214369] risk.  Data 
will be compared to source documents within the Investigator’s site.  Where any discrepancies are noted, the discrepancy will  be resolved 
with the Investigator and/or an individual designated by [CONTACT_737].  When the data are incomplete, attempts will be made  to obtain 
the missing data.  
 Data Security  
Limited study personnel will have access to study data stored on the institutional forms ite account, and minimum password complexity 
requirements will be enforced, and recaptcha and two -factor authentication provide additional layers of security. Formsite servers are 
co-located in a cloud -based architecture with amazon web services (aws). All  data stored on formsite are encrypted using the aes -256 
encryption algorithm, and high -grade sha -256 rsa encryption is used for https connections over tls. Secure network access is enforced 
by [CONTACT_7163] -tiered firewalls, custom system configurations and multi -zones networks. Grant Dornan, Center for Orthopaedic -Based 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page76 Outcomes,  Director, manages institutional access to the TSC formsite account, and creates sub -user accounts that enable access to 
individual form(s) for specific research studies.  
 
Standard of car e patient questionnaire data is automatically exported from formsite.com onto The Steadman Clinic (TSC) server and 
into the TSC patient outcomes database. Upon successful transfer, questionnaire data is automatically deleted from formsite.c om. 
Formsite use s secure “https” links by [CONTACT_869935], and no personally identifiable information (PII) is  
recorded through any website technologies on formsite.com.  
 Qualification of Study Staff  
All study staff will be confirmed to be qu alified as assigned to appropriately delegated study tasks. A Delegation of Authority Log will 
be kept at the study site in addition to documentation of applicable training and experience.  
 Training  
Prior to initiating the study, all site personnel will und ergo thorough training regarding the Protocol . Documentation of training will be 
retained at the  study site.  
 Protocol Amendments  
No changes in the study procedures shall be affected  without mutual agreement of the Investigator and the applicable IRB.   All protocol 
amendments must be documented in writing, including the date and justification for the change.  All changes must be documented by 
[CONTACT_869936] , which will be submitted to the FDA as appropriate . 
 Handling of Study Medication  
18.8.[ADDRESS_1214370] randomized. A 
prescription will be provided by [CONTACT_869937] d the number of 
pi[INVESTIGATOR_869894].  
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page77  
The study medication label will contain the following elements: Protocol IRB #, PI [CONTACT_5627], Name [CONTACT_869949], Directions, and 
the statement, “Caution – New Drug Limited by [CONTACT_12201].”  
 
 
18.8.2  Accountability  
A medication tracking sheet will be kept by [CONTACT_869917][INVESTIGATOR_78700], which is to include the lot number, expi[INVESTIGATOR_320]: date 
Vail Health Hospi[INVESTIGATOR_869895], name [CONTACT_869950], date dispensed, name [CONTACT_869951], 
randomization code, subject initials,  number of capsules dispensed, date and number of returned capsules, name [CONTACT_869952], 
date and number discarded and by [INVESTIGATOR_412937] m the capsules were discarded.  
18.8.3    Disposition of Unused Study Medication  
 
All unused , not previously dispensed  Study Medication will be returned to the Study Sponsor for proper dispos al or reallocation.  
1. For remaining previously dispensed Study M edication, the label (including identifiable information) is taken off of the bottle 
and discarded in a shred bin  by [CONTACT_869938] ; 
2. Any remaining  previously dispensed  Study M edication is  discarded in a secure biohazard bin  by [CONTACT_869938] ; 
3. Unused Study Medication that was not dispensed will be returned to the Study Sponsor to be stored or reallocated until the 
Study Medication expi[INVESTIGATOR_6054].  Upon expi[INVESTIGATOR_1516], the Study Medication  will then be discarded in a secure biohazard bin.  
4. Biohazard is pi[INVESTIGATOR_380865] d up for disposal on a weekly basis.  
 Laboratory Qualification  
All available information regarding laboratory qualification name [INVESTIGATOR_1238] a copy of the medical license for laboratory directors, current 
normal ranges for the laboratory and proof of appropriate laboratory certification as appropriate will be maintained in the regulatory 
binders.  
 
  
Clinical Protocol No. [ADDRESS_1214371] simila r 
confidentiality from his/her staff and the Institutional Review Board.  study documents (Protocols, and other material) will be stored 
appropriately to ensure their confidentiality.   
 
 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page79 20.0 Declaration of Helsinki  
The study will be conducted according to the guidelines established in the Declaration of Helsinki  (World Medical Association 1964) .  
Good Clinical Practices (GCPs) and local ethical and legal requirements.  Subjects will be free to withdraw from the study at any stage 
without prejudice to their subsequent treatment.   
 
 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page80 21.0 References  
 
1 Zhu, Y.  et al.  The Achilles' heel of senescent cells: From transcriptome to senolytic drugs. Aging Cell  14, 644 -658, 
doi:10.1111/acel.[ZIP_CODE] (2015).  
2 Acosta, J. C.  et al.  A complex secretory program orchestrated by [CONTACT_293170]. Nat Cell 
Biol 15, 978 -990, doi:10.1038/ncb2784 (2013).  
3 Coppe, J. P. , Desprez, P. Y., Krtolica, A. & Campi[INVESTIGATOR_16616], J. The senescence -associated secretory phenotype: the dark side of tumor 
suppression. Annu Rev Pathol  5, 99-118, doi:10.1146/annurev -pathol -121808 -102144 (2010).  
4 Coppé, J. P.  et al.  Senescence -associated secretor y phenotypes reveal cell -nonautonomous functions of oncogenic RAS and the 
p53 tumor suppressor. PLoS Biology  6, 2853 -2868 (2008).  
5 Kuilman, T. & Peeper, D. S. Senescence -messaging secretome: SMS -ing cellular stress. Nature Reviews Cancer  9, 81-94 
(2009).  
6 Xu, M.  et al.  Targeting senescent cells enhances adipogenesis and metabolic function in old age. eLife , 10.7554/eLife.[ZIP_CODE] 
(2015) . 
7 Karsdal, M. A.  et al.  Disease -modifying treatments for osteoarthritis (DMOADs) of the knee and hip: lessons learned from 
failures and opportunities for the future. Osteoarthritis Cartilage  24, 2013 -2021, doi:10.1016/j.joca.2016.07.017 (2016).  
8 Mora, J . C., Przkora, R. & Cruz -Almeida, Y. Knee osteoarthritis: pathophysiology and current treatment modalities. J Pain Res  
11, 2189 -2196, doi:10.2147/JPR.S154002 (2018).  
9 Farr, J. N.  et al.  Causal role of senescent cells in mediating age -related bone loss.  ( Sumitted).  
10 Farr, J. N.  et al.  Targeting cellular senescence prevents age -related bone loss in mice. Nat Med , doi:10.1038/nm.4385 (2017).  
11 Gao, S. G.  et al.  Correlation between senescence -associated beta -galactosidase expression in articular cartilage and disease 
severity of patients with knee osteoarthritis. Int J Rheum Dis  19, 226 -232, doi:10.1111/1756 -185X.[ZIP_CODE] (2016).  
12 Price, J. S.  et al.  The role of c hondrocyte senescence in osteoarthritis. Aging Cell  1, 57-65 (2002).  
13 Zhou, H. W., Lou, S. Q. & Zhang, K. Recovery of function in osteoarthritic chondrocytes induced by p16INK4a -specific 
siRNA in vitro. Rheumatology (Oxford)  43, 555 -568, doi:10.1093/rheu matology/keh127 (2004).  
14 Xu, M.  et al.  Transplanted Senescent Cells Induce an Osteoarthritis -Like Condition in Mice. J Gerontol A Biol Sci Med Sci  72, 
780-785, doi:10.1093/gerona/glw154 (2017).  
[ADDRESS_1214372] -traumatic osteoarthritis and creates a 
pro-regenerative environment. Nat Med  23, 775 -781, doi:10.1038/nm.4324 (2017).  
16 Lee, B. Y.  et al.  Senescence -associated beta -galactosidase is lysosomal beta -galactosidase. Aging Cell  5, 187 -195, 
doi:10.1111/j.1474 -9726.2006.[ZIP_CODE].x (2006).  
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page81 17 Song, M.  et al.  Muscle -derived stem/progenitor cell dysfunction in Zmpste24 -deficient progeroid mice limits muscle 
regeneration. Stem Cell Res Ther  4, 33, doi:10.1186/scrt183 (2013).  
18 Pendas, A.  M. et al.  Defective prelamin A processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase -
deficient mice. Nat Genet  31, 94-99, doi:10.1038/ng871 (2002).  
[ADDRESS_1214373] Progeria 
Syndrome. Mol Cell Biol  37, doi:10.1128/MCB.[ZIP_CODE] -16 (2017).  
20 Brittberg, M., Tallheden, T., Sjogren -Jansson, B., Lindahl, A. & Peterson, L. Autologous chondrocytes used for articular 
cartilage repair: an update. Clin Orthop Relat Res , S337 -348 (2001).  
21 Brown, T. D., Johnston, R. C., Saltzman, C. L., Marsh, J. L. & Buckwalter, J. A. Posttraumatic osteoarthritis: a first estima te of 
incidence, prevalence, and burden of disease. J Orthop Trauma  20, 739 -744, doi:10.1 097/01.bot.[PHONE_18026].[ZIP_CODE].ef (2006).  
[ADDRESS_1214374] -Turner, T., Wikstrom, E. A. & Palmieri -Smith, R. M. Epi[INVESTIGATOR_869896]. J 
Athl Train  52, 491 -496, doi:10.4085/1062 -6050 -51.5.08 (2017).  
23 Glasson, S. S., Blanchet, T. J. & Morris, E. A. The surgical destabilization of the medial meniscus (DMM) model of 
osteoarthritis in the 129/SvEv mouse. Osteoarthritis Cartilage  15, 1061 -1069, doi:10.1016/j.joca.2007.03.006 (2007).  
24 Yousefzadeh, M. J.  et al.  Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine  36, 18-28, 
doi:10.1016/j.ebiom.2018.09.015 (2018).  
25 Zhu, Y.  et al.  New agents that target senescent cells: the flavone, fisetin, and the BCL -XL inhibitors, A1331852 and 
A1155463 . Aging (Albany NY) , doi:10.[ZIP_CODE]/aging.101202 (2017).  
26 Si, D.  et al.  Mechanism of CYP2C9 inhibition by [CONTACT_811601]. Drug Metab Dispos  37, 629 -634, 
doi:10.1124/dmd.108.023416 (2009).  
27 Adhami, V. M., Syed, D. N., Khan, N. & Mukhtar, H. Dietar y flavonoid fisetin: a novel dual inhibitor of PI3K/Akt and mTOR 
for prostate cancer management. Biochem Pharmacol  84, 1277 -1281, doi:10.1016/j.bcp.2012.07.012 (2012).  
28 Khan, N., Syed, D. N., Ahmad, N. & Mukhtar, H. Fisetin: a dietary antioxidant for hea lth promotion. Antioxid Redox Signal  
19, 151 -162, doi:10.1089/ars.2012.4901 (2013).  
29 Maurya, B. K. & Trigun, S. K. Fisetin Modulates Antioxidant Enzymes and Inflammatory Factors to Inhibit Aflatoxin -B1 
Induced Hepatocellular Carcinoma in Rats. Oxid Med C ell Longev  2016 , 1972793, doi:10.1155/2016/1972793 (2016).  
30 Zheng, W.  et al.  Fisetin inhibits IL -1beta -induced inflammatory response in human osteoarthritis chondrocytes through 
activating SIRT1 and attenuates the progression of osteoarthritis in mice. Int Immunopharmacol  45, 135 -147, 
doi:10.1016/j.intimp.2017.02.009 (2017).  
31 Alghadir, A. H., Anwer, S., Iqbal, A. & Iqbal, Z. A. Test -retest reliability, validity, and minimum detectable change of visual 
analog, numerical rating, and verbal rating scales f or measurement of osteoarthritic knee pain. J Pain Res  11, 851 -856, 
doi:10.2147/JPR.S158847 (2018).  
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page82 32 Briggs, T. W.  et al.  Histological evaluation of chondral defects after autologous chondrocyte implantation of the knee. J Bone 
Joint Surg Br  85, 1077 -1083 (2003).  
33 Lysholm, J. & Wiklander, J. Injuries in runners. Am J Sports Med  15, 168 -171, doi:10.1177/036354658701500213 (1987).  
34 Bellamy, N., Buchanan, W. W., Goldsmith, C. H., Campbell, J. & Stitt, L. W. Validation study of WOMAC: a health status 
instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with 
osteoarthritis of the hip or knee. J Rheumatol  15, 1833 -1840 (1988).  
35 Galanos, A. N., Fillenbaum, G. G., Cohen, H. J. & Burchett, B. M. The  comprehensive assessment of community dwelling 
elderly: why functional status is not enough. Aging (Milano)  6, 343 -352 (1994).  
36 Ware, J., Jr., Kosinski, M. & Keller, S. D. A 12 -Item Short -Form Health Survey: construction of scales and preliminary tests of 
reliability and validity. Med Care  34, 220 -233 (1996).  
37 Braun, H. J. & Gold, G. E. Diagnosis of osteoarthritis: imaging. Bone  51, 278 -288, doi:10.1016/j.bone.2011.11.019 (2012).  
[ADDRESS_1214375] total knee 
arthroplasty: A single -blind randomized controlled trial. Arch Phys Med Rehabil  85, 546 -556 (2004).  
39 Parent, E. & Moffet, H. Comparative responsiv eness of locomotor tests and questionnaires used to follow early recovery after 
total knee arthroplasty. Arch Phys Med Rehabil  83, 70-80 (2002).  
40 Parent, E. & Moffet, H. Preoperative predictors of locomotor ability two months after total knee arthroplast y for severe 
osteoarthritis. Arthritis Rheum  49, 36-50, doi:10.1002/art.[ZIP_CODE] (2003).  
41 Montgomery, P. S. & Gardner, A. W. The clinical utility of a six -minute walk test in peripheral arterial occlusive disease 
patients. J Am Geriatr Soc  46, 706 -711 (1998 ). 
42 Steffen, T. M., Hacker, T. A. & Mollinger, L. Age - and gender -related test performance in community -dwelling elderly 
people: Six -Minute Walk Test, Berg Balance Scale, Timed Up & Go Test, and gait speeds. Phys Ther  82, 128 -137 (2002).  
43 Podsiadlo, D.  & Richardson, S. The timed "Up & Go": a test of basic functional mobility for frail elderly persons. J Am 
Geriatr Soc  39, 142 -148 (1991).  
44 Cesari, M.  et al.  Prognostic value of usual gait speed in well -functioning older people -results from the health, aging and body 
composition study. J Am Geriatr Soc  53, 1675 -1680, doi:DOI 10.1111/j.1532 -5415.2005.[ZIP_CODE].x (2005).  
45 Guralnik, J. M., Ferrucci, L., Simonsick, E. M., Salive, M. E. & Wallace, R. B. Lower -Extremity Function in Persons over the 
Age of 70 Years as a Predictor of Subsequent Disability. New Engl J Med  332, 556 -561 (1995).  
46 Guralnik, J. M.  et al.  A short physical performance battery assessing lower e xtremity function: association with self -reported 
disability and prediction of mortality and nursing home admission. J Gerontol  49, M85 -94 (1994).  
47 Liu-Ambrose, T.  et al.  Resistance Training and Executive Functions A 12 -Month Randomized Controlled Trial.  Arch Intern 
Med 170, 170 -178 (2010).  
 
  
Clinical Protocol No. [ADDRESS_1214376] anterior approach: a gait analysis study. Clin Biomech (Bristol, Avon)  24, 812 -818, 
doi:10.1016/j.clinbiomech.2009.07.010 (2009).  
49 Mudge, S., Barber, P. A. & Stott, N. S. Circuit -based rehabilitation improves gait endurance but not usual walking activity in 
chronic stroke: a randomized controlled trial. Arch Phys Med Rehabil  90, 1989-1996, doi:10.1016/j.apmr.2009.07.015 (2009).  
50 Bohannon, R. W. Comfortable and maximum walking speed of adults aged 20 -79 years: reference values and determinants. 
Age Ageing  26, 15-19 (1997).  
51 Jette, A. M., Jette, D. U., Ng, J., Plotkin, D. J. & Bac h, M. A. Are performance -based measures sufficiently reliable for use in 
multicenter trials? Musculoskeletal Impairment (MSI) Study Group. J Gerontol A Biol Sci Med Sci  54, M3 -6 (1999).  
52 Tager, I. B., Swanson, A. & Satariano, W. A. Reliability of physica l performance and self -reported functional measures in an 
older population. J Gerontol a -Biol 53, M295 -M300 (1998).  
53 Hirsch, C. H.  et al.  Correlates of performance -based measures of muscle function in the elderly: The cardiovascular health 
study. J Geron tol a-Biol 52, M192 -M200 (1997).  
54 Mangione, K. K., Craik, R. L., Tomlinson, S. S. & Palombaro, K. M. Can elderly patients who have had a hip fracture perform 
moderate - to high -intensity exercise at home? Physical Therapy  85, 727 -739 (2005).  
55 Osternig, L. R. Isokinetic dynamometry: implications for muscle testing and rehabilitation. Exerc Sport Sci Rev  14, 45-80 
(1986).  
 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page84 22.0 Appendices  
 Appendix A: Informed Consent  
 
 
Research Information and Consent for Participation in Biomedical Research  
Senolytic Drugs Attenuate Osteoarthritis -Related Articular Cartilage Degeneration: A Clinical Trial  
Study #: 2019 -16 
 
 
I. Overview:  You are being asked to take part in a research study.  The information in this document should help you to decide 
whether you w ant to participa te in this study.  The sections in this Overview provide the basic information about the study.  
More detailed information is provided in the remainder of the document.  
 
Study Staff : The Principal Investigator  [INVESTIGATOR_869897] y is [CONTACT_869962] A. Evans, MD , who is a physician at The Steadman Clinic  and 
who will lead the study team . Other approved  and appropriately qualified  research staff may act on behalf of the Principal 
Investigator.  
 
Study Details : This study is being conducted at The Steadma n Clinic and Steadman Philippon Research Institute  and is 
supported by [CONTACT_869939]: Office of Naval Research . The purpose of the study is to test a n 
investigational drug called Fisetin  in patients with knee osteoarthritis to improve joint health and reduce pain . If you are already 
a patient of one of the study doctors ([CONTACT_21148], [CONTACT_32246], [CONTACT_869957], [CONTACT_869955], or [CONTACT_869963]) , you may have 
already undergone a knee physical exam , X-rays and/or an MRI,  and completed questionnaires that can be used for this study. 
All other exams, procedures , and treatments that are part of the research study will be provided at no cost to you . 
 
If you are not currently a patient of one of the above listed study doct ors, a study doctor will meet with you to evaluate your knee 
pain and determine if you have a condition called knee osteoarthritis. They will order a knee x -ray and do a physical exam of 
you knee to make this determination. This will only be done after you  sign this consent form and the costs will be covered by 
[CONTACT_15365].  
 
For established patients of the study doctors and new patients, research procedures i nclude:   
 
February 16, 2021 , V14  

 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page85  
 
• Random assignment into either the Fisetin group or pla cebo group . You will be provided either Fisetin  (the 
investigational drug)  or placebo tablets  for 2 treatment cycles  over the course of  2 months ; 
• Pregnancy test  
• Blood draw ; 
• Knee X -rays;  
• Magnetic resonance imaging (MRI);  
• Functional performance testing;  
• Physical exam ;  
• Muscle strength testing;  
• Lower -extremity video -motion analysis ; 
• Knee questionnaires . 
 
Participants : You are being asked to take part because you have been diagnosed with a painful joint condition called knee 
osteoarthritis . If you agree to participate in this study, your involvement will last for 18 months (1 year and 6 months).  
Voluntary Participation : Your participation in this research is voluntary. You do not have to participate and may stop 
your participation at any time. Your decision whether or not to participate will not affect your current or future dealings 
with The Steadman Clin ic. If you decid e to participate, you are free to withdraw at any time without affecting that 
relationship.  Alternatives to participating in the study do exist and can be discussed with the study team doctors . These 
strategies may or may not preclude you from participatin g in the study .  
Benefits, Compensation, and Risks : We do not know if you will receive any benefit from your participation. If you are assigned 
to the placebo treatment group , you are not expected to directly benefit from participating in  this research. You will receive a 
$[ADDRESS_1214377] for each visit that requires you to return to the study site for research purposes. The total value is $ [ADDRESS_1214378] serious risk that may be related to taking part in this 
research is that the new treatment (Fisetin) may not be effective or as effective as current standard of care procedures  to manage 
your knee osteoarthritis . Some of the common standard of care procedures include intra -articular steroid injection, over the 
counter non -steroidal anti -inflammatory drug administration (such as aspi[INVESTIGATOR_156699]), or autologous biologics therapi[INVESTIGATOR_014]  
(injections of products derived from your own blood or bone marrow) . You may consult your do ctor for more information 
regarding these treatment alternatives. Another risk is that you may not be part of the treatment group and thus receive a pl acebo 
(non-active) drug. Known potential s ide effects of taking Fisetin  or placebo , although very uncommo n, include: nausea, dry  
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page86 mouth, diarrhea, vomiting, and fatigue. The common drug interactions and warnings include: (1) lowering the effectiveness of 
other medications you may be taking, such as anti -coagulant, anti -diabetic, anti -hypertensive, and anti -seizure medications; (2) 
developi[INVESTIGATOR_869898]; and/or (3) restlessness if you consume high amounts of caffeine or tobacco products while taking 
Fisetin.  
 
Confidentiality : Even if we publish the findings from this study, we will keep your individual stud y information private and 
confidential.  Anyone with the authority to look at your records must keep them confidential.  
 
 
II. Conflict of Interest  
 
If you are currently receiving care at The Steadman Clinic, y our health care provider may be  an investigator on this research protocol, 
and as an investigator, is interested in both your clinical welfare and in the conduct of this study. Before entering this st udy or at any 
time during the research, you may ask for a second opi[INVESTIGATOR_869899] e from a clinician who is not associated with this project. You 
are not obligated to participate in any research project offered by [CONTACT_496026]. Your participation in this research study  is voluntary , 
and you do not have to pa rticipate. The decision to not participate will not affect your clinical care now or in the future.  
 
Neither the study doctors  nor any members of the research team have any financial relationships with any manufacturer or supplier of 
Fisetin.  
 
Johnny Huard, PhD is the Principal In vestigator on the contract of all four of our studies funded by [CONTACT_2315] (DOD), 
including this one. While [CONTACT_869959] is the lead PhD scientist on the four DOD -funded studies, Thos Evans, MD, a physician, is the 
principal investigator [INVESTIGATOR_869900]. ProofPoint Biologics (PPB)  is an operating division  of the Steadman 
Clinic that may draw and prepare your blood for analysis.  
 
Some of [CONTACT_869959]’s compensation is covered by [CONTACT_869940]. [CONTACT_869964] is the medical dire ctor and part owner of PPB. [CONTACT_869965] is a part owner of PPB.  However, their financial interest in and/or part ownership of PPB  will not affect the research procedures or 
outcomes of this study.  
 
III. Why am I being asked to participate in this research?  
 
You have been asked to participate in the research because you have a painful joint condition called knee osteoarthritis.  

 
  
Clinical Protocol No. [ADDRESS_1214379] of The Steadman Clinic  and the Steadman Philippon Research 
Institute . 
Even though you agree to participate in this study and complete the informed consent,  the study doctor may decide that you  are not 
eligible to  participat e in this study.  
You are eligible to participate in this study if you:   
• Are 40-80 years of age;  
• Are willing to comply with all study related procedures and assessments;  
• Have been diagnosed with knee osteoarthritis.  
You are not eligible to participate in this study if you:  
• Are unable to take oral medications;  
• Are pregnant or nursing a child;  
• Women who plan on becoming pregnant during the dosing of fisetin or placebo;  
• Have a medical condition or history that, in the opi[INVESTIGATOR_689] : 
o Might constitute a risk for participation in the study , 
o Could interfere with the stu dy objectives, conduct, or evaluation  of the study, or  
o Could prevent you from fully participating in all aspects of the study;  
• Have previously undergone recent surgery or injections to your knee;  
• Are currently taking any medications that may be incompatibl e with Fisetin use;  
• Are unable to safely undergo an MRI  (due to metal implants , severe claustrophobia , or body size) . 
 
• Behavioral Modification – You will be encouraged to reduce use  caffeine use (i.e. coffee, soda, tea)  by 50% prior to and 
during the 2 -day study drug dosing periods. Due to interaction s with fisetin and caffeine, your body may not clear caffeine  
from your system as effectively as normal . 
 
IV. Study Procedures: What will happen during this study?  
 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page88 This research will be performed at The Steadman Clinic, Steadman Philippon Research Institute , and Vail Health . 
 
Fisetin is a commercially available dietary supplement  that is found in many plants, such as fruits and vegetables. The common side -
effects and drug -to-drug interactions of Fisetin are generally  understood by [CONTACT_869941].  Dietary supplements do not require 
approval from the Food and Drug Administration (FDA); however, we have received approval from the FDA to study Fisetin as a 
treatment for patients with knee  pain due to  osteoarthritis and for this reason, Fisetin is referred to as an investigational drug in this 
consent form .  
 
You will be asked to tak e Fisetin or placebo capsules for 2 cycles of treatment  over the course of approximately  5 weeks:  
• Cycle 1: 2 day on (days 1 and 2), followed by 28 days off (day 30).  
• Cycle 2: 2 days on (days 31 and 32).  
 
You will need to come to the study site 4 more  times  over the next 12 months , for a total of five visits in all . Each r esearch visit will 
take between  1 and 4 hours to complete.  
 
Procedure Visits:  
If you are an existing patient of one of the study doctors , the physical exams, medical record review , and questionnaire collection are 
part of standard of care procedures at The Steadman Clinic  and may be used to determine eligibility and for Visit [ADDRESS_1214380] to  you. 
 
Visit 1 (Pre -Treatment/Enrollment)  
• Time frame : Immediately  
• Visit length : 2-3 hours  
• A clinical member of the study  team  will determine if you are eligible to participate . If you're an existing patient, a  clinical team 
member will access your medical records to collect information about you and your medical history. This will in clude any 
medications you currently take and other information in your medical records related to your condition or treatment that may be 
important to your participation in the study.  If you are not an existing patient, a member of the clinical team will a sk you about 
yourself and your medical history to determine your eligibility.  
• A pregnancy test will be performed for all pre -menopausal female  participants.  
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page89 • If you do not have recent x -rays on file, you will have x -rays taken of your knees.  
• You will have a 50% chance of being randomly assigned to one of the two treatment groups:  
1. Fisetin group (investigational group);  
2. Placebo group (control group).  
o  “Randomization”: How we decide which study group you will be in  
▪ This study will assign all part icipants to one of two different treatment groups. To decide which group you will 
be in, we will use a method of chance. This method, called randomization, is like flippi[INVESTIGATOR_007] a coin or rolling dice.  
o “Double -Blind”: You will not know which group you are in  
▪ You will not know which study group you are in, and neither will your study doctor. Therefore, this study is called 
“double -blind.” Your group assignment needs to be kept secret so that the study is based on scientific results and 
not on peoples’ opi[INVESTIGATOR_6153]. However, we can obtain your group assignment if you have an emergency. If you have 
an emergency, make sure you tell the emergency staff about your participation in this study.  They can 
contact [CONTACT_3019], and we will give them all relevant information.  
o What the pl acebo in this study is:  
▪ The placebo is a pi[INVESTIGATOR_869901]; it will have no medical  effect on you . 
• You will have your blood drawn to colle ct 50 milliliters ( 10 teaspoons) of  blood for lab screenings and protein testing.  
 
Visit 2 (Treatment)   
• Time frame : within 3 months of Visit 1  
• Visit l ength : 3-4 hours  
• Vital  signs , medication information , and any adverse events that occurred since  the last visit will be collected.  
• A pregna ncy test will be performed for all pre -menopausal female  participants.  
• The following procedures and tests will be performed:   
▪ Medication instructions;  
▪ Magnetic resonance imaging (MRI) scan;  
▪ Functional performance testing;  
▪ Physical exam ; 
▪ Muscle strength testing;  
▪ Video -motion analysis.  
• Note that the blood test and knee x -ray may be performed at this visit if it was not done at visit 1.  
• Some of the screening procedures may need to be repeated for accuracy , fidelity , and/or safety . 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page90 • Vail Health Pharmacy will be responsible for dispensing the Fisetin or placebo capsules. Fisetin or placebo capsules will be 
given to you in a bottle with a set of instructions.  
• After completing the study tests for this visit , you will be given Fisetin or placebo capsules as treatment. You will be instructed 
to take capsules while at the study site and the next day (10 -15 capsules per day, amount based on body weight) . You will be 
instructed to take the capsules for 2 cycles of treatment:  
o Cycle 1: 2 day s on (days 1 and 2), followed by 28 days off (day 30).  
o Cycle 2: 2 days on (days 31 and 32).  
o Treatment will occur over the course of approximately  5 week s.  
• All capsules must be taken within [ADDRESS_1214381] capsule is consumed.  
• At Visit 4, please return any remaining capsules in the bottle. These extra capsules will be counted and discarded at your next 
on-site visit.  
• You will be given a drug diary/schedule to log each dose you take during the 2 treatment cycles.  
• A member of the clinical  team will contact [CONTACT_869942] s while you are  scheduled to  take Fisetin or placebo to 
remind you of the schedule and record any adverse events you may experience. Depending on the severity of the adverse event, 
the member of the clinical team may request that you visit the study site for further evaluation.  
  
Non-Visit, Pain Questionnaire  
• Time Frame:  Every [ADDRESS_1214382] dose of and once w eekly for the following 6  weeks  
• Length:  5 minutes  
• You will complete an electronic pain questionnaire every [ADDRESS_1214383] dose.  
• If you are unable to fill out the questionnaire electronically, we will provide you with a paper form at Visit 2.  
 
Visit 3  (Blood Draw)   
• Time frame : 2 weeks (±  2 days) from your first dose of Fisetin or Placebo  
• Visit length : 1 hour  
• You will have your blood drawn to  collect 50 milliliters ( 10 teaspoons)  of blood for lab screenings and protein testing.  
 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page91 Visit 4 (Testing)   
• Time frame : 2 weeks (± 10 days) from your LAST  dose of Fisetin or Placebo  
• Visit length : 1-2 hours  
• You will return any extra capsules in the medication bottle at this visit.  
• Vitals, medication information, a knee questionnaire , and any adverse events that occurred during the treatment course will be 
collected.  
• You will have your blood drawn to  collect  50 milliliters ( 10 teaspoons)  of blood for lab screenings and protein testing.  
• The following procedure will be performed:   
▪ Physical exam . 
 
Visit 5 (Testing)  
• Time frame : 6 months (±  4 weeks ) from your FIRST  dose 
• Visit length : 3-4 hours  
• Vital  signs , medication information, a knee questionnaire , and any adverse events that occurred over the last [ADDRESS_1214384] ed.  
• You will have your blood drawn to collect  50 milliliters ( 10 teaspoons)  of blood for lab screenings and protein testing.  
• The foll owing procedures and tests will be performed:   
▪ MRI scan;  
▪ Functional performance testing;  
▪ Physical exam ; 
▪ Muscle strength testing;  
▪ Video -motion analysis.  
 
 
Visit 6 (Testing)   
• Time frame : 12 months (±  4 weeks ) from your FIRST  dose 
• Visit length : 3-4 hours  
• Vital signs , medication information, a knee questionnaire , and any adverse events that occurred over the last 12 months will be 
collected.  
• You will have your blood drawn to collect 50 milliliters ( 10 teaspoons)  of blood for lab screenings and protein testing.  
• The following procedures and tests will be performed:   
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page92 ▪ MRI scan;  
▪ Functional performance testing;  
▪ Physical exam ; 
▪ Muscle strength testing;  
▪ Video -motion analysis.  
 
Non-Visit,  Pain Questionnaire  
• Time Frame:  [ADDRESS_1214385] dose  
• Length:  20-30 minutes  
• You will complete an electronic knee questionnaire  
If you are unable to fill out the questionnaire electronically, we will provide you with a paper form . 
Alternative Procedures:  
If at any time you wish to seek an alternative treatment due to overt pain or functional deficiency, you may consult with your study 
doctor  regarding treatment options. I f prescribed by [CONTACT_4904], you would be  allowed to receive a corticosteroid intra -articular knee 
injection at any time during the study and remain enrolled in the study. If you wish to seek an alternative therapy other tha n a 
corticosteroid intra -articular knee injection, ( e.g., a biologics -based therapy  or surgery ), you will be removed f rom the study.  You or 
your health insurance plan  would be responsible for the c osts of any alternative procedures.  
 
Research Subject Responsibilities:  
As a research subject in this study, it is important that you:  
• Tell your doctor or clinical team member if your condition or circumstances change during the study;  
• Return to the site for scheduled study visits;  
• Call the doctor’s office to:  
o Report any injuries, hospi[INVESTIGATOR_602], emergency room visits, abnormal symptoms (including severe nausea, diarrhea, 
vomiting, chills, excessive swelling) , or complaints;  
o Schedule an upcoming  visit or reschedule a  missed research visit.  
 
Please call [ADDRESS_1214386] your study doctor  for any immediate assistance.  
 
Study Procedures:  
1. Pregnancy Test:  You will complete a urine pregnancy test.  
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page93 2. Blood Draw:  A certified phlebotomist will insert a needle into your vein and will collect 5 0 milliliters ( 10 teaspoons) of blood. 
Your blood samples will be used to assess your health and measure proteins within y our blood.  
3. Medication Instructions:  A member of the study  team will provide you with the medication tablets at Visit 2. You will be 
instructed to take tablets (amount based on body weight) for 2 days and then again for 2 days 4 weeks later.  You will need t o 
store the medications at room temperature. You will be given a set of instructions and a drug diary/schedule to log the follo wing:  
▪ Date;  
▪ Time of day tablets were taken;  
▪ Number of tablets taken.  
4. X-ray: If you do not have  recent knee x -rays on file with the clinic, you will undergo a standard, 3 -view x -ray sequence of both 
knees.  
5. Magnetic Resonance Imaging (MRI):  A scan in a [ADDRESS_1214387] given a safety screening questionnaire to determine if you 
are a candidate for this procedure. If you meet the criteria, a technician will prepare you for the MRI scan. A set of headph ones 
will be given to you and a device will be set up over your knee. Once the technician has prepared you for the MRI scan, you will 
be moved into the scanner. The scans will take up to half an hour each time.  
6. Functional Performance:  Researchers will assess the coordination of you r knee joints, strength, and control by [CONTACT_869943]. Researchers will measure distance, time , or number of times you are able to complete the 
test. Each of the tests will be repeated three times:  
▪ Stair -Climbing Test:  This is a timed test that will assess how quickly you walk up and down 12 stairs.   
▪ Timed Up and Go:  This is a timed test that will assess how quickly you can stand up from an armed chair, walk 3 meters 
(approximately 9 feet), turn, and sit back down without  physical assistance.  
▪ [ADDRESS_1214388] Walk:  This is a timed test that will assess how quickly you can walk 4 meters (approximately 13 feet).  
▪ 6 Minute Walk:  This is a timed test that will assess the distance you can walk in 6 minutes.  
7. Physical exam:  A proces s in which a medical professional will evaluate your knee joint for any signs of injury. This procedure 
will take approximately [ADDRESS_1214389] and range of motion assessment.  
8. Muscle Strength:  Muscle strength will  be assessed for both knees using a strength testing system.   You will be escorted from the 
Steadman Philippon Research Institute Biomotion lab to Howard Head (which is located on the same floor as the Biomotion lab) 
where the strength testing system is located.  You will be placed in a seated position with joint stabilizing cushions. You will be 
asked to flex and extend your knee while contracting your muscles. The first time will be a warm -up. This test will be repeated 
3 times.  
9. Biomotion/Video -Motion Analysis : The movement of your joints will be measured in the Biomotion Lab of the Steadman 
Philippon Research Institute during two common activities:  
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page94 ▪ Walking on a treadmill:  You will be asked to walk for 5 short periods of time (les s than 1 minute each) on a treadmill. 
The treadmill speed will be set to 1 meter per second (2.2 miles per hour), which is slower than the average walking 
speed of  [ADDRESS_1214390] betwee n walks if necessary.  
▪ Ascending and descending stairs:  You will be asked to walk up and down a short (4 -step) stairway at your own pace, 
using handrails if needed. This activity will be performed [ADDRESS_1214391] ing, you will wear reflective markers attached using double -sided tape (Figure 1). The motion of these markers 
will be tracked using a n 18-camera video -motion capture system and will be used to determine the three -dimensional motion of 
your joints. You wil l be dressed in snug -fitting exercise clothes so that markers placed on clothing will not move excessively 
relative to the skin (the lab will provide compression clothing if you do not have your own).  
 
  
 
 
 
 
Figure 1: Approximate locations of marker placement 
(grey dots) for video motion analysis. Note: You will be 
given compression shorts to wear throughout testing 
and will wear a close -fitting shirt or sports bra , if 
applicable. Markers will be placed on skin or clot hing 
where necessary.  
 
 
10. Self-Reported Pain Questionnaire (Short -Form):  A questionnaire that assesses your knee pain will be provided to you 
electronically every [ADDRESS_1214392] dose of and once w eekly for the following 6  weeks  in an e -mail or on an 
iPad tablet  or in paper form. This procedure will take approxim ately 5 minutes to complete.   
11. Self-Reported Knee Questionnaire (Long -Form):  A questionnaire that assesses your knee’s function will be provided to you 
electronically in a n e-mail or on an iPad  tablet  or in paper form. This procedure will take approximately [ADDRESS_1214393] the following health information for research purpose s at the 
time o f your evaluation:  
• Gender  
• Age  
• Height  
• Weight  
• Body mass index (BMI)  
• Smoking status  
• Chronic diseases or conditions (not related to your current knee condition)  
• Medication use such as non -steroidal anti -inflammatory drugs  (e.g., aspi[INVESTIGATOR_248], ibuprofen, etc.)  
 
The study team also asks permission to access your medical record to collect the following injury information for research pu rposes 
from your imaging and surgical reports:  
• Pre-existing injury details  
• Severity of injury details  
• Imaging findings (X -ray or MR I) 
• Injury type  
• Previous treatment details (related to your current knee condition)  
 
 
V. What are the potential risks and discomforts?  
 
There are risks associated with participation in this study.  These risks are listed below, but it’s possible that some risk s are not yet 
known.  
 
Side Effects Associated with Fisetin: A clinical member of the study team will describe the possible side effects of Fisetin and answer 
any questions you may have. The common side effects for Fisetin, although very uncommon, include: reduced appetite, altered a ctivity, 
nausea, dry mouth, diarrhea, vom iting, and fatigue. We do not anticipate the occurrence of serious side effects with the prescribed 
treatment regimen in this study. However, we have identified a variety of drug interactions  with  Fisetin. The study team will review 
 
  
Clinical Protocol No. [ADDRESS_1214394] be en identified at this time; some may be mild or others very serious. Everyone taking part in this study will be watched close ly 
for any side effects.  If you experience any unexpected behavior changes or unpleasant symptoms, please contact [CONTACT_869944]. If you use tobacco or high amounts of caffeine (>1000 mg/day),  a member of the study team  will describe the possible 
complications or adverse events when taking Fisetin (such as sleep problems and/or restlessness) . As a precaution, we advise that you 
limit the amount of caffeine and tobacco products while taking Fisetin or placebo during the 2 dosing periods (two periods of 2 days 
separated by 4 weeks) . 
 
Fisetin was shown to cause DNA damage to human cells in the te st tube. The relevance of this result to the study in which you are 
participating is unknown.  
 
Risks Associated with Placebo Group Assignment: It is unknown whether  Fisetin  will provide a beneficial effect for the treatment of 
knee osteoarthritis. Therefor e, there is no known risk for NOT receiving Fisetin.  Some of the common side effects of placebo treatment 
include: reduced appetite, altered activity, nausea, dry mouth, diarrhea, vomiting, and fatigue.  
 
Risk of Improper Disclosure of Y our Personal Information: There is a possibility that your personal information will be accidentally 
or inappropriately breached during this research. The Steadman Cl inic and Steadman Philippon Research Institute use many physical, 
technologic , and adminis trative measures to protect your information. Locking offices and cabinets protect information on paper, while 
password -locked workstations and encryption protect electronic information.  Whenever possible, information will be used and analyzed 
in a manner that does not contain any of your identifiable information.  When results of this research are presented at scientific meetings 
and in medical journals, all information that can possibly identify you will be removed.  
 
Risk or Discomforts Associated with the Blood Draw: The following potential  risks are associated with the collection of blood: 
fainting, fatigue, lightheadedness, dizziness and nausea, and pain or possible infection at the blood -draw site. Clinical precaut ions will 
be in place to monitors these associated risks.  
 
Risks associated with the Knee X -Ray: An anterior (front) view x -ray of your knee s is required to determine the extent of osteoarthritis 
in your knee. If you have been treated for a knee disorder at The Steadman Clinic, you will probably have had an x -ray taken of your 
knee as part of your clinical care which can be used for this resear ch. If you do not have a recent knee x -ray on file, an anterior knee x -
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page97 ray will be acquired as part of this research study. The radiation exposure from this x -ray is less than half of what is received from a 
typi[INVESTIGATOR_869902] x -ray. As part of every day living, everyone is exposed to a small amount of background radiation from space 
and naturally occurring radioactive minerals. The radiation dose you will receive in this study (0.002 mSv or less) will give  your body 
the equivalent of a  few hour s’ wort h of this natural radiation.  
 
This radiation exposure may not be required for your medical care but is necessary to obtain the research information desired . There is 
no dose of ionizing radiation which is considered to be free of risk. However, there is n o evidence to suggest that the small levels of 
radiation involved in this study have measurable adverse effects. The risks from radiation exposure to your knee are low beca use there 
are no sensitive organs exposed.  
 
 
Risks or Discomforts Associated with MR I: The MRI scan involves loud noises and positioning in a small space. You may feel 
claustrophobic, tired, or nauseated, especially if you are uncomfortable with tight spaces. The MRI scan does not involve the  use of X -
rays or injectable dyes. There are no  known reports of increased cancer or birth defects associated with this procedure. However, the 
MRI scan exposes you to high magnetic fields, which can be dangerous if you have a pacemaker or certain metal implants.  
 
Risk of Injury and Discomfort with Fun ctional Performance , Muscle Strength, and Video -motion Analysis Testing : This study 
involves completion of activities which are common during daily life. These activities are unlikely to cause additional injur y at the time 
you will be completing them. Howe ver, there is a chance of accidental injury during these activities, such as falling, pulling a muscle, 
or other injury. It is also possible that these movements could cause some discomfort, pain, or fatigue consistent with physi cal exercise. 
If at any tim e during data collection you do not feel that you can safely complete an activity, you must stop and tell a researcher 
immediately. Your safety and well -being are more important than the researchers’ data.  
Risk of Skin Irritation:  Motion capture markers are attached to the skin with double -sided tape, which may cause minor skin irritation.  
Risks or Discomforts Associated with Self -Reported Questionnaires and Physical Exam: There is a potential risk of emotional distress 
associated with questionnaires and pain and/or discomfort associated with the physical exam. However, these risks should not exceed that  
experienced during normal activities of daily living.  
 
VI. Are there reproductive risks to participation in this study?  
 
If you are a  woman:  Participating in this research may involve risks to pregnant women and/or an unborn baby [CONTACT_869945]. To protect against possible side effects of the study drug Fisetin, you may not take part in this study if you  are pre gnant 
 
  
Clinical Protocol No. [ADDRESS_1214395] two method of birth control 
or to be abstinent (i.e., not have sex) throughout the study.  Acceptable methods of birth control include: oral contraceptive and condom, 
intra-uterine device (IUD) and condom, diaphragm with spermicide and condom. If you think that you have become pregnant during 
the study, you must tell the doctor immediately.  
 
If you are a man:  To protect against possible side ef fects of the study drug to an unborn baby, you must not get a partner pregnant 
while taking the study drug and for [ADDRESS_1214396] dose. Acceptable methods of birth 
control include: oral contraceptive and condom, intra -uterine device (IUD) and condom, diaphragm with spermicide and condom.  
 
VII. What are the possible benefits of the  study?  
 
This study is designed for the researcher to learn more about Fisetin. This study is not designed to treat any illness or to improve your 
health.  
 
VIII. Are there alternative treatments?  
 
There may be other ways of treating your knee osteoarthritis. These other ways might include  medication, injections, or surgery.  You 
could also choose to get no treatment at all.  
 
You should talk to your doctor about your choices. Make sure you understand  all of your choices before you decide to participate in this 
study. You may leave this study and still have these other choices available to you.  
 
IX. What are the costs for participating in this research?  
 
If you are already an established patient with one of the study doctors, w ith the exception of the data collected at Visit 1, all physical 
exams and self -reported questionnaires are collected for research purposes. All other procedures and treatments are part of the research 
study and will be provided at n o cost to you. For example , no-cost services include every treatment (Fisetin or placebo), procedure, and 
evaluation following the initial visit.  
If you were not already a patient with one of the study doctors and heard about this study from a flyer or advertisement, all  procedures 
and treatments are part of the research study and will be provided at no cost to you. 
 
  
Clinical Protocol No. [ADDRESS_1214397] received , please contac t Suzanne Page at 970 -401-8770 .  
 
X. Will I be paid for my participation in this research?  
 
You will receive a $[ADDRESS_1214398] for each completed follow -up study visit  (Visits 3, 4, 5 and 6) . If you do not finish the study, 
you will be compensated for th e visits you have completed. If you complete the study, you will receive a total of $ 100 in Amazon Gift 
cards.  You will receive your payment by a member of the study team at the end of each research visit.  
 
XI. What if I am injured as a result of my participa tion?  
 
If you get ill or injured from being in the study, your study doctor  will help you get medical treatment. You should let the study doctor 
know right away that you are ill or injured. If you believe you have become ill or injured from this study, you should contac t  your study 
doctor  at (970) [ADDRESS_1214399] not set aside any money to pay you or to pay for your treatment 
if you get ill or injured from being in the study. There are no plans for The Steadman Clinic and Steadman Philippon Research Institute  
to provide other forms of compensation (such as lost wages or pain and suffering) to you for research related illnesses or injuries. The 
only exception to this policy is if it is proven that your injury or illness is directly caused by [CONTACT_247594] a Steadman Clinic and 
Steadman Philippon Research Institute  employee.  
 
By [CONTACT_3368], you are not giving up any legal rights to seek compensation of injury.  
 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page100  XII. Can I withdraw or be removed from the study?  
 
Taking part in this study is voluntary. You have the right to choose not to take part in thi s study. If you decide to participate, you are 
free to withdraw your consent and discontinue participation at any time without affecting your future care at The Steadman Cl inic. You 
will still receive standard of care treatment for your condition if you vo lunteer to withdraw.  
 
You have the right to leave a study at any time without penalty.  If leaving could affect your safety, the investigator will provide 
information about recommended steps for leaving the study.   
 
The researchers also have the right to stop your participation in this study without your consent if they believe it is in your best interest.   
 
XIII. Future use of identifiable private information  
 
Your identifiers might be removed from your private records.  Your information could be used and/or di stributed to another investigator 
for future research studies without additional consent from you.  We use your blood samples  only for purposes directly related to this 
study. Any remaining samples will be destroyed upon study completion .  
 
XIV. What about your privacy and confidentiality?  
 
The people who will know that you are a research subject are members of the research team, and if appropriate, your physician s and 
nurses.  No information about you, or provided by [CONTACT_10825], during the research, will be disclos ed to others without your written permission, 
except if necessary to protect your rights or welfare (for example, if you are injured and need emergency care) or if require d by [CONTACT_2371].  
 
Study information which identifies you and the consent form signed by [CONTACT_288246]/or copi[INVESTIGATOR_869903] r esearch 
by:  
• Food and Drug Administration (FDA)  
• Department of Defense , Office for Human Research Protections (OHRP)  
• Vail Health In stitutional Review Board  
 
A possible risk of the research is that your participation in the research or information about you and your health might bec ome known 
to individuals outside the research.  Your original signed consent document and relevant medical information will be added to your 
Medical Record at The Steadman Clinic.  All other  personal information that will be collected for this study will be stored separately 
 
  
Clinical Protocol No. [ADDRESS_1214400] -protected  access limited to authorized personnel on the study team . The information collected for 
research only will be maintained for up to two years following completion of the study  (or longer, if required by [CONTACT_869946]) . De-identified data and information entered into the Medical Record may be kept indefinitely.  
When the results of the research are published or discussed in conferences, no information will be included that would reveal  your 
identity.  
 
A description of this clin ical trial will be available on http://www.ClinicalTrials.gov , as required by U.S. law. This website will not 
include information that can identify you. At most, the website will include a summary of the results. You can search this website at any 
time.  
 
 
XV. What happens if new information becomes available about the study?  
 
During the course of this study, we may find more information that could be important to you. This includes information that, 
once learned, might cause you to change your mind about being in this study. We will notify you as soon as possible if such 
information becomes available.  
We may learn things about you from the study activities that could be impo rtant to your health or to your treatment, meaning 
they are “clinically significant .” By [CONTACT_4907], you will receive blood tests and MRI s that are for research purposes 
only and are not part of your clinical car e. These research tests  will not be read  or evaluated  by a health care professional and 
will not be added to your medical records (they are used exclusively for research data processing). If a researcher notices a n 
anomaly in any of these tests that might indicate a serious, life -altering condition they will notify the Principal Investigator. The 
Principal Investigator [INVESTIGATOR_869904], which may include consulting with an expert such as a radiologist  or 
cardiologist , to determine if the finding is likely to have enough  health importance to disclose it to you. If it is determined that this 
information should be reported to you, the Principal Investigator [INVESTIGATOR_869905], referral to another clinic, physician or provider , or information about alternative 
resources for obtaining care.   
The above results will not be placed in your medical record. You may need to meet with professionals with expertise to help y ou 
learn more about your research results. The study team/study will not cover the costs of any follow -up consultations or actions.  If 
you are not interested in receiving this information, please do not consent to participate in this study.  
 
 
  
Clinical Protocol No. [ADDRESS_1214401] que stions about the research?  
 
Contact [CONTACT_289760] 970 -476-1100:  
• if you have any questions about this study or your part in it,   
• if you feel you have had a research -related injury  (or a bad reaction to the study treatment), and/or  
• if you have questions, concerns , or complaints about the research.  
 
XVII. Who should I contact [CONTACT_39646] I have questions about my rights as a research subject?  
 
If you have questions about your rights as a research subject or concerns, complaints, or to offer input you may call Mary Crumbaker, 
Chief Ethics and Compliance Officer at Vail Health at [ADDRESS_1214402] any of your treatment  or any other treatment, healthcare, enrollment in health plans , or eligibility 
for benefits.  
 
What information will be obtained a nd used?  
“Patient information” means the health information in your medical or other healthcare records. It also includes information in your 
records that can identify you. For example, it can include your name, address, phone number, birthdate, and medica l record number.  
By [CONTACT_3368] , you are giving permission to the following organization(s) to disclose your patient information for use in this 
research.  
• Vail Health (includes Shaw Cancer Center, Howard Head and all Diversified Services clinic locat ions)  
• The Steadman Clinic  
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page103  • Steadman Philippon Research Institute  
 
What information will be released for research use?  
If you give your permission and sign the last page of this form, you are allowing the health care providers indicated above t o release the 
following medical records containing your Personal Health Information to the researchers for use in this project. Your Person al Health 
Information includes  health information in your medical records, financial records and other information that  can identify you.  
 
The specific information that will be released and used for this research is described below : 
• Medical history / treatment  
• Consultation  
• Diagnostic imaging report  
• Radiology images (like X -rays or CT scans or MRI’s)  
• Laboratory / diagnostic  tests 
• Operative reports (about an operation)  
• Patient -reported outcomes from questionnaires  
• Basic demographic information:  
▪ Gender  
▪ Age  
▪ Height  
▪ Weight  
▪ Body mass index (BMI)  
▪ Smoking status  
• Medical comorbidities (presence of two chronic diseases or conditions)   
 
How will my patient information be used?  
The following groups of people may also be able to see your health information and may use that information to conduct this r esearch:  
• The research team for the research described in the Consent Form;  
• Vail Health Institutional Review Board (VH IRB);  
• Others who are required by [CONTACT_869947], including U. S. government agencies 
such as The U.S. Food and Drug Administration (FDA) or the Department of Defense Office of Human Research 
Protections . 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page104   
Your patient information will be used and/or given to others for the following reasons:  
• To do the research  
• To study the results, and  
• To see if the research was done right  
 
If the results of this study are made public, informat ion that identifies you will not be used.  
The researcher will use your patient information only in the ways that are described in the research consent form that you si gn and as 
described in this HIPAA Authorization.   
You can ask questions about what the research team will do with your information and how they will protect it.  
The privacy laws do not always require the receiver of your information to keep your information confidential.  After your information 
is given to an organization that is not subj ected to the privacy laws, e.g. , a research organization, there is a risk that it could be shared 
without your permission.  
 
How long will this authorization be valid?  
 
This permission for the researchers to obtain your patient information:    
• Ends when the research is complete and any required monitoring of the study is finished.  
 
Cancelling your permission:  
 
You may change your mind at any time. To take back your permission, you must send your written  request to:  
Kate Wilmouth  
Steadman Philippon Researc h Institute  
[ADDRESS_1214403]. 
But they can’t obtain more health information about you for this r esearch unless it is required by a federal agency that is monitoring the 
research.  
 
 
  
Clinical Protocol No. [ADDRESS_1214404] read (or someone has read to me) the above information. I have been given an opportunity to ask questions and my questions 
have been answered to my satisfaction. I agree to participate in this research and authorize the use of my health information  as outlined 
above. I will be given a copy of this signed and dated form.  
 
 
 
Signature [CONTACT_869953]. [ADDRESS_1214405] has provided legally effective informed consent.  
 
 
 
Signature [CONTACT_50660]  
(must be the PI [INVESTIGATOR_869906], NP, or PA)   
 
Date (must be same as subject’s)  
 
 
Printed Name [CONTACT_869954]. 2019 -16 
Version 00 7, June 11, 2021  
Page108   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page109   
 Appendix B – Study Schemata  
 
 

 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page110   
 Appendix C-Augmented Numerical Rating Scale  
  
  

 
  
Clinical Protocol No. 2019 -16 
Version 00 7, June 11, 2021  
Page111   
 
 
 
 Appendix D:  Potential Drug Interactions with Fisetin  
Fisetin has been demonstrated to have inhibitory activity of cytochrome P450  
 
Fisetin has been demonstrated to have inhibitory (competitive mainly) activity of cytochrome 
P450 isozymes especially CYP2C9 and CYP3A4. CYP2C9 is an important cytochrome P450 
isozyme with a majo r role in the oxidation of both xenobiotic and endogenous compounds. 
CYP2C9 makes up about 18% of the cytochrome P450 protein in liver microsomes  (data only 
for antifungal) . Some 100 therapeutic drugs are metabolized by [CONTACT_097]2C9, including drugs with 
a narro w therapeutic index such as warfarin and phenytoin and other routinely prescribed drugs 
such as acenocoumarol, tolbutamide, losartan, glipi[INVESTIGATOR_7130], and some nonsteroidal anti -
inflammatory drugs. CYP3A4 is a critical hepatic “first -pass” metabolism enzyme for a litany 
of drugs including Fisetin which is estimated to be responsible for approximately 40 -50% of 
Fisetin’s bioavailability loss upon oral administration. As a competitive inhibitor of CYP3A4, 
Fisetin can thus significantly modulate the serum concentrat ions of other co -administered 
drugs that have narrow therapeutic ranges, potentially leading to adverse effects. Several 
classes of drugs are metabolized by [CONTACT_9058] P450 isozymes. These again include anti -
coagulants (i.e. warfarin or Acenocoumarol), dia betes drugs or gluco -regulatory drugs (i.e. 
Tolbutamide or Glucotrol), anti -seizure drugs (i.e. Phenytoin or Dilantin). To accommodate 
for this, we have constructed an exclusion criteria to mitigate these effects and provide a list 
of drugs known to intera ct with crucial CYPs that must be withheld for 2 days prior to Fisetin 
dosing and during Fisetin administration.   
 
 
 
 
 